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A B S T R A C T
Background
Reducing high blood cholesterol, a risk factor for cardiovascular disease (CVD) events in people with and without a past history of CVD
is an important goal of pharmacotherapy. Statins are the first-choice agents. Previous reviews of the effects of statins have highlighted
their benefits in people with CVD. The case for primary prevention was uncertain when the last version of this review was published
(2011) and in light of new data an update of this review is required.
Objectives
To assess the effects, both harms and benefits, of statins in people with no history of CVD.
Search methods
To avoid duplication of effort, we checked reference lists of previous systematic reviews. The searches conducted in 2007 were updated
in January 2012. We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (2022, Issue
4), MEDLINE OVID (1950 to December Week 4 2011) and EMBASE OVID (1980 to 2012 Week 1).There were no language
restrictions.
Selection criteria
We included randomised controlled trials of statins versus placebo or usual care control with minimum treatment duration of one year
and follow-up of six months, in adults with no restrictions on total, low density lipoprotein (LDL) or high density lipoprotein (HDL)
cholesterol levels, and where 10% or less had a history of CVD.
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Data collection and analysis
Two review authors independently selected studies for inclusion and extracted data. Outcomes included all-cause mortality, fatal and
non-fatal CHD, CVD and stroke events, combined endpoints (fatal and non-fatal CHD, CVD and stroke events), revascularisation,
change in total and LDL cholesterol concentrations, adverse events, quality of life and costs. Odds ratios (OR) and risk ratios (RR)
were calculated for dichotomous data, and for continuous data, pooled mean differences (MD) (with 95% confidence intervals (CI))
were calculated. We contacted trial authors to obtain missing data.
Main results
The latest search found four new trials and updated follow-up data on three trials included in the original review. Eighteen randomised
control trials (19 trial arms; 56,934 participants) were included. Fourteen trials recruited patients with specific conditions (raised
lipids, diabetes, hypertension, microalbuminuria). All-cause mortality was reduced by statins (OR 0.86, 95% CI 0.79 to 0.94); as was
combined fatal and non-fatal CVD RR 0.75 (95% CI 0.70 to 0.81), combined fatal and non-fatal CHD events RR 0.73 (95% CI
0.67 to 0.80) and combined fatal and non-fatal stroke (RR 0.78, 95% CI 0.68 to 0.89). Reduction of revascularisation rates (RR
0.62, 95% CI 0.54 to 0.72) was also seen. Total cholesterol and LDL cholesterol were reduced in all trials but there was evidence of
heterogeneity of effects. There was no evidence of any serious harm caused by statin prescription. Evidence available to date showed
that primary prevention with statins is likely to be cost-effective and may improve patient quality of life. Recent findings from the
Cholesterol Treatment Trialists study using individual patient data meta-analysis indicate that these benefits are similar in people at
lower (< 1% per year) risk of a major cardiovascular event.
Authors’ conclusions
Reductions in all-cause mortality, major vascular events and revascularisations were found with no excess of adverse events among
people without evidence of CVD treated with statins.
P L A I N L A N G U A G E S U M M A R Y
Statins for the primary prevention of cardiovascular disease
Cardiovascular disease (CVD), which comprises heart attacks (myocardial infarction), angina and strokes, is ranked as the number one
cause of mortality and is a major cause of morbidity world wide. High blood cholesterol is linked to CVD events and is an important risk
factor. Reducing high blood cholesterol, is thus an important way to reduce the chances of suffering a CVD event. Statins - cholesterol
lowering drugs - (e.g. simvastatin, pravastatin, atorvastatin) are the first-choice treatments. Since the early statin randomised controlled
trials were reported in the 1990s, several reviews of the effects of statins have been published highlighting their benefits particularly in
people with a past history of CVD. Benefits include a reduction in CVD events. Statins have also been shown to reduce the risk of
a first event in otherwise healthy individuals at high risk of CVD (primary prevention) but information on possible hazards has not
been reported fully. The aim of this updated systematic review is to assess the effects, both in terms of benefits and harms of statins,
for the primary prevention of CVD. We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and
EMBASE until 2011. We found 18 randomised controlled trials with 19 trial arms (56,934 patients) dating from 1994 to 2008. All
were randomised control trials comparing statins with usual care or placebo. The mean age of the participants was 57 years (range
28 - 97 years), 60.3% were men, and of the eight trials that reported on ethnicity, 85.9 % were Caucasian. Duration of treatment
was a minimum one year and with follow-up of a minimum of six months. All-cause mortality and fatal and non-fatal CVD events
were reduced with the use of statins as was the need for revascularisation (the restoration of an adequate blood supply to the heart)
by means of surgery (coronary artery bypass graft ) or by angioplasty (PTCA). Of 1000 people treated with a statin for five years, 18
would avoid a major CVD event which compares well with other treatments used for preventing cardiovascular disease. Taking statins
did not increase the risk of serious adverse effects such as cancer. Statins are likely to be cost-effective in primary prevention.
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B A C K G R O U N D
Burden of cardiovascular disease
Cardiovascular disease (CVD) encompasses a wide range of disease
including coronary heart disease (e.g. heart attack, angina), cere-
brovascular disease (ischaemic and haemorrhagic stroke), raised
blood pressure, hypertension, rheumatic heart disease and heart
failure. In the context of this review the major causes of CVD
are unhealthy diets, tobacco use and physical inactivity (WHO
2008).
CVD is ranked as the number one cause ofmortality and is amajor
cause of morbidity world wide accounting for 17 million deaths,
30% of total deaths. Of these, 7.6 million are due to heart attacks
and 5.7 million due to stroke (WHO 2008). Over 80% of CVD
deaths occur in low- and middle-income countries (WHO 2008).
In developing countries, it causes twice a many deaths as HIV,
malaria and tuberculosis combined (Gaziano 2007). It has been
estimated that between 1990 and 2020, the increase in ischaemic
heart disease alonewill increase by 29% inmen and48% inwomen
in developed countries and by 120% in women and 127% in men
in developing countries (Yusuf 2001). CVD imposes high social
costs, including impaired quality of life and reduced economic
activity and accounts for a large share of health service resources
(Gaziano 2007).
CVD is multi-factorial in its causation and lifestyle changes are
the basis of any treatment strategy, with patients often requiring
behavioural counselling. Those unable to achieve ormaintain ade-
quate risk reduction through lifestyle changes alone or those at high
risk may benefit from pharmacotherapy. High blood cholesterol
(hypercholesterolaemia) is a risk factor for both fatal and non-fatal
CVD events in people with and without a past CVD (Prospective
Studies Collaboration 2007), and lowering cholesterol, in par-
ticular low density lipoprotein (LDL) cholesterol, is an impor-
tant target for pharmacotherapy. Statins are the first-choice agents
for LDL cholesterol reduction. Since the relation between blood
cholesterol and cardiovascular risk is continuous (Chen 1991),
there is no definite threshold to initiate treatment. If a threshold
for ’high’ cholesterol is set at over 3.8 mmol/L, (146.9 mg/dL) this
would contribute 4.4 million deaths worldwide and 40.4 million
disability-adjusted life years (DALYs) (Ezzati 2002). Furthermore,
the average level of blood cholesterol within a population is an
important determinant of the CVD risk of the population. Differ-
ences in average levels of blood cholesterol between populations
are largely determined by differences in diet, and countries with
higher dietary saturated fat intake and a lower ratio of polyunsat-
urated to saturated fatty acids have higher than average cholesterol
levels (Davey Smith 1992).
Trial evidence for use of statins
Since the early statin trials were reported in the early 1990s, sev-
eral reviews of the effects of statins have been published highlight-
ing the benefits of their use (Baigent 2005; Bartlett 2003; Blauw
1997; Briel 2004;Cheung 2004; Ebrahim1999;Katerndahl 1999;
LaRosa 1994; LaRosa 1999; Law 2003; Pignone 2000; Silva 2006;
Thavendiranathan2006;Ward 2007;Wilt 2004). TheCholesterol
Treatment Trialists (CTT) Collaboration has used individual pa-
tient data in their meta-analyses to show consistency of treatment
benefits across a wide range of patient subgroups (Baigent 2005).
More recent evidence from the CCT Collaboration has demon-
strated that statins are beneficial in reducing the risk ofCVDevents
in people without prior evidence of CVD (CTT Collaboration
2010). A 2012 CTT Collaboration report further demonstrated
a consistent 20% relative risk reduction in major vascular events
with statins per 1mmol/L reduction in LDL cholesterol, regardless
of baseline risk (CTT Collaboration 2012a). Men and women,
old and young, and people with and without CVD all appear to
benefit. These findings confirm the efficacy of statins for primary
prevention, resolving concerns about possible serious adverse ef-
fects and potential sources of bias in the randomised trials high-
lighted in an earlier version of this Cochrane review.
Adverse effects of statins
There has been some concern, primarily from observational stud-
ies, that low levels of blood cholesterol increase the risk of mortal-
ity from causes other than coronary heart disease (CHD), includ-
ing cancer, respiratory disease, liver disease and accidental/violent
death. Several studies have now demonstrated that this is mostly,
or entirely, due to the fact that people with low cholesterol lev-
els include a disproportionate number whose cholesterol has been
reduced by illness - early cancer, respiratory disease, gastrointesti-
nal disease and alcoholism, among others (Iribarren 1997; Jacobs
1997). Thus it appears to be the pre-existing disease which causes
both the low cholesterol and raisedmortality (Davey Smith 1992).
The potential adverse effects of statins among people at low risk
of CVD were poorly reported and unclear in earlier trials (Jackson
2001), but among those with and without pre-existing CVD the
evidence now suggests that any possible hazards are far outweighed
by the benefits of treatment. Two reviews of 18 and 35 trials respec-
tively found that there were similar rates of serious adverse events
with statins as compared to placebo (Kashani 2006; Silva 2006).
Individual patient data meta-analyses conducted by the CTTCol-
laboration have demonstrated unequivocally that there is no excess
risk of cancers (CTT Collaboration 2012b), confirming the find-
ings of an earlier review and has reported reductions in all-cause
mortality and no excess of non-vascular mortality (Dale 2006).
Rhabdomyolysis - break down of muscles - which can be serious
if not detected and treated early (Beers 2003) may be caused by
statins, but this is very rare. In a systematic review of randomised
trials of statinswith about 35,000 people and 158,000 person years
of observation in both treated and placebo groups, rhabdomyoly-
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sis was diagnosed in eight treated and five placebo patients, none
with serious illness or death (Law 2003).
An increased risk of incident type 2 diabetes associated with statin
therapy compared with usual care or placebo has been reported
(Mills 2011; Sattar 2010) and with high dose versus usual dose
statins (Preiss 2011). The mechanism by which statins may in-
crease diabetes risk is not known. Haemorrhagic stroke appears to
be increased by statin treatment, although estimates are imprecise,
with an annual risk of 0.5 per 1000 patients treated for five years
which is small compared with the benefits seen on the overall risk
of stroke (CTT Collaboration 2012a). Two recent meta-analyses
of large-scale placebo or standard care controlled trials observed a
9% increased risk for incident diabetes associated with statin ther-
apy, with little heterogeneity between studies. In Mills 2011(Mills
2011), 17 randomised controlled trials (RCTs) reported an in-
creased risk of the development of diabetes.
Other possible adverse events derived from small trials have been
investigated. In a recent RCT of 1016 adults, statin treatment for
six months was associated with increased self-reporting of reduced
energy and fatigue on exertion (Golomb 2012). An earlier RCT of
621 adults found that statins did not adversely affect self-reported
quality of life, mood, hostility, psychological well being or anger
expression (Wardle 1996). Small decrements in scores on tests of
psychomotor speed and attention were found by Muldoon et al in
an RCT of 209 adults, butMuldoon concluded thatmore research
is needed to fully evaluate this (Muldoon 2000). In addition, a sys-
tematic review of five statin trials (N = 30,817) found no evidence
that statins increased the risk of death from non-illness mortality
(accidents, violence or suicide) (Muldoon 2001).
Guidelines for use of statins
The evidence on the beneficial effects of statins has led expert
committees to promote their use on a global scale particularly in
the developed world. (Genest 2009; Manuel 2006; NICE 2006;
Reiner 2011) Statin prescribing and expenditure have risen rapidly
as a result. For example, the European statin prescription average
(weighted by population of each country) increased from 11.12
defined daily doses/1000 in 1997 to 41.80/1000 in 2002, an aver-
age 31% increase a year (Walley 2004). The expenditure on statin
drugs in England was over £20 million in 1993, over £113 million
in 1997 (Ebrahim 1998) and has risen to more than £500 million
in 2006 (NICE 2006).
Why it is important to do this review
Amajor limitation of the evidence summaries to date is combining
trials of statins in secondary and primary prevention of CVDwith-
out reporting benefits and adverse effects separately. A number of
systematic reviews have focused on statins in primary prevention,
but they differ in their interpretation of the evidence (Brugts 2009;
Ebrahim 1999; NICE 2006; Thavendiranathan2006; Vrecer,
2003; Ward 2007). This is largely due to the differing inclusion
criteria of the reviews and differences in reporting of outcomes.
The most recent systematic review, using individual participant
data from themajority of statin trials, provides strong evidence that
benefits from statins outweigh any possible serious adverse effects,
even at very low levels of CVD event rates (CTT Collaboration
2012a). These new findings counter earlier opinion that the evi-
dence is insufficient to support use of statins in primary prevention
for women or in older men (Abramson 2007). Previous reviews,
in addition, have not reported other relevant outcomes such as
costs, patient quality of life nor have they focused their attention
on detailed reporting of adverse side effects.
The aim of this systematic review is to update and include further
trials that have been published since the last search (to 2007) and
contextualise our findings with those recently published by the
CTT Collaboration.
O B J E C T I V E S
To update this review to assess the effects, both harms and benefits,
of statins in people with no history of CVD events.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) comparing treatment with
statins for at least 12 months with placebo or usual care. Length
of follow-up of outcomes had to be at least six months.
Types of participants
Men and women (aged 18 or more) with no restrictions on total,
low or high density lipoprotein cholesterol levels. We limited our
inclusion of study population to have less than or equal to 10% of
a previous history of CVD (this would include previous angina,
myocardial infarction and/or stroke). Trials in which statins were
used to treat or control chronic conditions (e.g. Alzheimer’s dis-
ease, rheumatoid arthritis, renal disease, macular degeneration,
aortic stenosis) were excluded.
Types of interventions
Statins (HMG CoA reductase inhibitors) versus placebo or usual
care.
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Concommitant interventions
Drug treatments and other interventions were accepted provided
they were given to both arms of the intervention groups. Adjuvant
treatments with one additional drug where a patient developed
excessively high lipids during the trial were accepted.
Types of outcome measures
The following outcomes were collected:
• death from all causes;
• fatal and non-fatal CHD, CVD and stroke events;
• combined endpoint (fatal and non-fatal CHD, CHD and
stroke events);
• change in blood total and low density lipoprotein (LDL)
cholesterol concentration;
• revascularisation;
• adverse events;
• quality of life;
• costs.
Search methods for identification of studies
Asprevious comprehensive reviews (Bartlett 2005; Ebrahim 1999;
Ward 2007) have been undertaken, we built on this work. The
searches conducted in 2007 (Appendix 1) were updated on 10th
January 2012 (Appendix 2). We searched the Cochrane Central
Register of Controlled Trials (CENTRAL) on The Cochrane Li-
brary (2011, Issue 4), MEDLINE OVID (1950 to December
Week 4 2011) and EMBASE OVID (1980 to 2012 Week 1). The
standard RCT filters used forMEDLINE and EMBASE (Lefebvre
1996) in 2007 were updated in 2012. The Cochrane sensitiv-
ity- and precision-maximising RCT filter has been applied to the
MEDLINE search (Lefebvre 2011) and the BMJ 2011 has been
applied to the EMBASE search. No language restrictions were ap-
plied to either searching or trial inclusion. Reference lists of iden-
tified review articles and of all included RCTs were searched to
find other potentially eligible studies.
Data collection and analysis
Trial selection
Two review authors independently read the results from searches
on electronic databases to identify those articles relevant to this
systematic review based on title or title and abstract (FT and KW
for the original review, FT and AM for the update). Full articles
were retrieved for further assessment. The articles were read in-
dependently by two review authors (FT and KW for the original
review, FT and AM for the update) and a form was designed to
describe the characteristics of studies to be included or excluded
as set out in the recommendations in the Cochrane Handbook for
Systematic Reviews of Interventions 5.0.2 (Higgins 2011).
Assessment of risk of bias
We used criteria described in the Cochrane Handbook of System-
atic Reviews 5.0.2 (Higgins 2011) to describe the quality of trials
we found. Two review authors independently assessed risk of bias
of selected studies (FT and KW for the original review, FT and
AM for the update). Any differences of opinion were resolved by
discussion and consensus and finally by discussion with a third
author (SE). To assess any risk of bias we focused on the following
dimensions as recommended in the Cochrane Handbook for Sys-
tematic Reviews of Interventions.
1. Adequate sequence generation (such as computer-generated
random numbers and random number tables, whilst inadequate
approaches included the use of alternation, case record numbers,
birth dates or days of the week).
2. Adequate measures to conceal allocation. Concealment was
deemed adequate where randomisation was centralised or
pharmacy-controlled, or where the following were used: serially
numbered containers, on-site computer-based systems where
assignment is unreadable until after allocation, other methods
with robust methods to prevent foreknowledge of the allocation
sequence to clinicians and patients
3. Blinding was deemed adequate if blinding was applied
(whether the participant, care provider or outcome assessors)
4. Completeness of outcome data was deemed adequate if
intention-to-treat analysis was performed for each outcome and
not what patient numbers the analysis was confined to.
5. Free of selective reporting was deemed adequate if all stated
outcomes were reported on and presented. We highlighted any
selective outcome reporting.
A ’Risk of bias’ graph for each trial was made available to assess
quality.
Data extraction
We designed a data extraction form and included data on our
outcomes measures in addition to:
• study ID;
• quality;
• population characteristics terms of CVD risk;
• intervention dosage and duration.
To assess baseline risk of CVD the following median/mean values
were also extracted:
• age;
• gender ratio;
• proportion of current smokers;
• total cholesterol and LDL cholesterol.
Data were independently extracted by two review authors (FT,
KW). Any differences of opinion were resolved by discussion and
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consensus and finally by discussion with a third review author
(SE).
Contacting trialists
For unpublished studies or where data were incomplete in pub-
lished papers, we contacted trial authors to obtain further details.
Data analysis
Risk ratios (RR), odds ratio (OR) and 95% confidence intervals
(CI) were calculated for dichotomous data. Quantitative analyses
of outcomes was based on ’intention-to-treat’ (ITT). For continu-
ous data (such as change in blood total cholesterol), we calculated
pooled mean differences (MD) (with 95% CI).
We did not add the number of fatal and non-fatal clinical events
together from any of the studies that we included in this review
as it was not possible to ascertain whether an individual who had
a non-fatal clinical event followed by a fatal clinical event was
counted as a clinical event under both categories. As a result, we
have only included the composite of fatal and non-fatal clinical
events if this was reported in the papers. For example, number
of stroke events: 10 trials reported this as a composite outcome,
but three reported on fatal and five on non-fatal stroke events. We
did not add the fatal and non-fatal strokes together to ascertain a
composite number.
Heterogeneity
Because trials found may not have been carried out according to a
commonprotocol therewill usually be variations in patient groups,
clinical settings, concomitant care etc. We, therefore, assessed het-
erogeneity between trial results. Trial data were considered to be
heterogeneous where the I2 statistic was > 50%. For analysis, we
used the fixed-effect method unless data were heterogenous in
which case we used the random-effects model. Where significant
heterogeneity was present, we attempted to explain the differences
based on the patient clinical characteristics and interventions of
the included studies.
Publication or other bias
A funnel plot was used to test for asymmetry, which represents
the presence of publication bias based on the data for the primary
outcome of all-cause mortality (Sterne 2001).
Analyses for potential effect modifiers was initially considered but
abandoned due to lack of adequate reporting. We planned to in-
clude:
• gender;
• extent of hyperlipidaemia;
• age greater than and less than 65 years.
Sensitivity analysis
Sensitivity analysis was used to explore the influence of the fol-
lowing on effect size:
• repeating analysis taking account of study quality;
• repeating analysis excluding any large studies to see how
they influence the results;
• post-hoc analysis (requested by a peer-reviewer) excluding
those trials with any participants with clinical evidence of CVD.
R E S U L T S
Description of studies
For the original review 4227 references were identified after re-
moval of duplicates. From reading titles and abstracts 4128 were
eliminated as being not relevant to the review. Full papers were ob-
tained for 99 references. From these 99 papers, 72 papers report-
ing on 48 studies were excluded (see Characteristics of excluded
studies). A total of 27 papers reporting on 14 trials were included
(see Characteristics of included studies).
For this update, 6442 references were identified after removal of
duplicates and off these, 131 full papers were retrieved. From these,
92 papers were relevant; 35 papers related to seven studies included
in the original review and 57 papers to five new trials. For one
of these (a conference abstract), we were unable to obtain further
data (Babes 2010). This study is listed the Table: Characteristics of
studies awaiting classification. We excluded 39 papers: 37 related
to 36 excluded studies and two related to the previously excluded
ASCOT-LLA trial (Figure 1). Reasons for exclusion remained un-
changed and mainly included; treatment length not at least be-
ing one year, more than 10% of the population having existing
CVD and no relevant outcomes (to this review) being reported
(see Characteristics of excluded studies).
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Figure 1. Study flow diagram for the update
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Our update identified four new trials with 19,662 additional
participants (Bone 2007; CERDIA 2004; METEOR 2010;
JUPITER 2008) bringing a total of 18 trials. Of the 18, trials, one
tested two different interventions and for the purpose for meta
analysis, this trial was counted as two trials (in total 19 trial arms)
(CELL A 1996; CELL B 1996). In addition, our updated search
identified reporting of new follow-up data of the three of the 14 tri-
als in the original review. (Adult Japanese MEGA Study; CARDS
2008; WOSCOPS).
The trials dated from 1994 to 2008 and were conducted world-
wide, mainly in industrially developed countries (Japan, USA, Eu-
rope and JUPITER which included sites in South America, Israel,
South Africa and Russia). Fourteen trials recruited patients with
specific conditions: nine recruited participants with raised lipids,
four with diabetes, two with hypertension and one with microal-
buminuria.
All tested the effectiveness of statins compared with placebo; nine
tested pravastatin 10 mg to 40 mg per day; two atorvastatin 10
mg to 80 mg per day; two fluvastatin 40 mg to 80 mg per day;
two lovastatin 20 mg to 40 mg per day; two rosuvastatin 20 mg
to 40 mg per day; and the remaining two simvastatin 20 mg to
40 mg per day (one of these had started patients on cerivastatin
0.4 mg per day which was replaced with simvastatin in August
2001). Five trials also included advice, counselling or information
on health-behaviour modification such as diet, smoking cessation,
or exercise.
In total, the 18 trials (with 19 trial arms) recruited 56,934 par-
ticipants and observed outcomes ranging from one to 5.3 years.
The size of the population recruited ranged from 47to 17,802.
The mean age of the participants was 57 years (range 28-97 years),
60.3% included male participants, and of the eight trials that re-
ported on ethnicity, 85.9 % were Caucasian.
Three trials (AFCAPS/TexCAPS 1998; CARDS 2008; JUPITER
2008) were stopped prematurely because significant reductions
in primary composite outcomes between the intervention and
placebo had been observed. Overall, these trials had recruited 47%
of the total study population and were stopped 1.4 to 3.0 years
before the pre-specified end date.
Data on all-cause mortality were provided in 11 trials. Excluding
the four trials whose primary outcomewas change in size of carotid
artery and one whose primary endpoint was change in bone den-
sity, nine of the remaining trials chose a composite primary out-
come. Ten trials provided data on fatal and 11 on non-fatal CHD
events, and five trials provided data on fatal and two on non-fa-
tal CVD events. Ten trials reported on combined stroke events,
five provided data on non-fatal and three on fatal stroke events.
Fourteen trials provided data on cholesterol and 12 on adverse
events. Four trials provided economic costings, (CARDS 2008;
JUPITER 2008; MRC/BHF Heart Protection; WOSCOPS) and
one (CELL A 1996; CELL B 1996) provided data on patient per-
ceived quality of life.
Excluding the four trials that solely recruited participants with
diabetes, 1% to 20% of the participants had diabetes. Excluding
the two trials that recruited participants with hypertension, the
remaining studies recruited 15% to 67% with hypertension. The
proportion of participants smoking ranged from 10% to 45% in
the 17 trials that provided these data. We were unable to ascertain
baseline lipid levels for three trials. Baseline total cholesterol levels
ranged from 4.81 to 6.97 mmol/L (median 6.17 mmol/lL, and
LDL cholesterol from 2.8 to 4.95 mm/L (median 4.1mm/L).
Risk of bias in included studies
In general, there was low risk of bias (Figure 2; Figure 3) though
all trials were either fully or partially funded by pharmaceutical
companies (five by Bristol Myers and Squibb, three by Pfizer, four
by Astra-Zeneca, two by Merck and one by Bayer, one by Bayer
and Merk, one by Pfizer, and the remaining by Sankyo Co Ltd).
Three (AFCAPS/TexCAPS 1998; ASPEN 2006; HYRIM 2007)
of the 19 trial arms did not provide adequate information on the
methods used for randomisation, two of which had recruitedmore
than 2,000 participants. Eighteen trials used blinding to reduce
bias, 15 of which used double-blinding methods. Thirteen used
intention-to-treat analysis. The drop-out rates ranged from 2%
to 30% for the 12 trials that reported on this. We judged 15 of
the trials to be free from selection bias. The MRC/BHF Heart
Protection Study (MRC/BHF Heart Protection) only provided
data on total CVD events for patients with diabetes in the primary
prevention group, and HYRIM reported outcomes on cholesterol
on a subset of the population (46%) with no explanation as to
how the subset had been derived (HYRIM 2007).
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Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Figure 3. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
The funnel plot for all-cause mortality showed no sign of asym-
metry (Figure 4).
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Figure 4. Funnel plot of comparison: 2 Mortality and Morbidity, outcome: 2.1 Total Mortality.
Effects of interventions
All-cause mortality
Thirteen trials with 48,060 participants recruited reported on total
mortality. During observation, 1077/24,408 (4.4%) died in the
statin group compared with 1223/23,652 (5.1%) in the placebo
group; number needed to treat for five years: 96 (95% confidence
interval (CI) 64 to 244). Only the JUPITER trial showed strong
evidence of a reduction in total mortality. When the data were
pooled using a fixed-effect model, a reduction that favoured statin
treatment by 14% was observed: (odds ratio (OR) 0.86, 95% CI
0.79 to 0.94). No heterogeneity was observed (Analysis 1.1).
Fatal and non-fatal CHD events
Fourteen trials with 48,049 participants reported on combined
fatal and non-fatal CHD events. Four trials showed evidence of a
reduction in this combined outcome, whichwas maintained in the
pooled analysis using a fixed-effect model: 820/24,217 (3.4%) in
the statin group versus 1114/23,832 (4.6%) in the placebo group.
Overall NNT for five years: 56 (95% CI 46 to 75); risk ratio (RR)
0.73 (95% CI 0.67 to 0.80) (Analysis 1.2).
Observations on fatal or non-fatal CHD events are based on 10
and 11 trials respectively. When pooled, a risk reduction in fatal
CHDevents was observed; 251/23,019 (1.1%) statin group versus
306/23,075 (1.3%) placebo group; RR 0.82 (95% CI 0.70 to
0.96) (Analysis 1.3). Evidence for a reduction in non-fatal CHD
eventswas also found: 398/20,668 (1.9%) statin group versus 583/
20,309 (2.8%); RR 0.67 (95% CI 0.59 to 0.76). No significant
heterogeneity was observed using a fixed-effect model for both
analyses (Analysis 1.4).
Fatal and non-fatal CVD events
Nine trials with 23,805 participants, representing 41.8% of the
total population, reported on combined fatal and non-fatal CVD
events. Four of the larger trials with 21,205 participants demon-
strated strong evidence of a reduction in this combined outcome.
In the pooled analysis using a fixed-effect model: 1103/11,892
(9.3%) in the statin group versus 1455/11,913 (12.2%) in the
placebo group; RR 0.75 (95% CI 0.70 to 0.81). There was no
evidence of heterogeneity (Analysis 1.5).
Five trials reported on fatal CVD events and two reported on
non-fatal CVD events. Reductions in risk were observed in both
these endpoints; fatal CVD events; 295/16,962 (17.4%) in the
statin group versus 355/17,050 (20.8%) in the placebo group; RR
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0.83 (95% CI 0.72 to 0.96) (Analysis 1.6); non-fatal CVD events
123/4,299 (3%) in the stain group versus 175/4,398 (4%) in the
placebo group, RR 0.77 (95% CI 0.62 to 0.96) (Analysis 1.7). No
significant heterogeneity was observed using a fixed-effect model
for both analyses.
Fatal and non-fatal stroke events
Ten trials with 40,295 participants reported on combined fatal
and non-fatal stroke events. Two trials that had been stopped pre-
maturely demonstrated a significant reduction in this combined
outcome with the use of statins. This reduction was observed in
the pooled analysis using a fixed-effect model: 345/20,302 (17%)
in the statin group versus 442/19,993 (22%) in the placebo group;
RR 0.78 (95% CI 0.68 to 0.89] (Analysis 1.8).
Three trials with 27,238 participants reported on fatal stroke
events, and five trials with 28,097 participants reported on non-fa-
tal stroke events. There was no observed difference in fatal stroke.
We applied a random-effects model due to significant heterogene-
ity (I2= 68%). Two of three trials had been prematurely stopped,
and the remaining trial (WOSCOPS) demonstrated a 43% in-
crease in risk of fatal stroke, but this was not significant (Analysis
1.9). Using a fixed-effect model, a significant risk reduction was
seen for non-fatal stroke events 193/14,243 (1.3%) in the statin
group versus 276/13,852 (2%) in the placebo group; RR 0.69
(95% CI 0.58 to 0.83) Analysis 1.10.
Combined fatal and non-fatal CHD, CVD and stroke
events
Only four trials with 35,254 participants reported a composite of
fatal and non-fatal events for CHD, CVD and stroke. All the trials
showed a significant reduction in this composite outcome with the
treatment of statins, which was maintained in the pooled analysis
and used a fixed model: 438/17,591 (2.4%%) events versus 678/
17,663 (3.8%); RR 0.65 (95% CI 0.58 to 0.73) (Analysis 1.11).
Revascularisation
Seven trials with 42,403 participants reported on the need
for revascularisation procedures during follow-up: 286/21,166
(1.4%) in the statin group versus 461/21237 (2.2%) in the placebo
group underwent either percutaneous transluminal coronary an-
gioplasty (PTCA) or coronary artery bypass graft (CABG). Three
of the larger trials were able to demonstrate fewer revascularisa-
tion events in the intervention groups compared with the con-
trol groups with the use of statins. This was maintained in the
pooled analysis using a fixed-effect model: RR 0.62 (0.54 to 0.72)
(Analysis 1.12).
Cholesterol
Fourteen trials provided data on total cholesterol, and 16 trials
provided data on LDL cholesterol. For both endpoints, all trials
were able to demonstrate significant reductions. For total choles-
terol, a net difference of -1.05 mmol/L (95% CI -1.35 to -0.76
mmol/L) was observed (Analysis 2.1), and for LDL cholesterol a
net difference of -1.00 (95% CI -1.16 to -0.85 mmol/L) was ob-
served (Analysis 2.2). There was marked heterogeneity of effects
in both analysis (I2= 100% and 99%, respectively). It is likely that
the heterogeneity is due to differences in the type of statin and
dosage used.
Adverse events
Twelve trials provided data on adverse events. In total 10,838/
56,934 (19%) participants experienced an adverse event with ad-
verse event rates ranging from 0% to 97%. Pooling the events
rates indicated no difference between the intervention and con-
trol groups with the use of statin using a fixed-effect model: RR
1.00 (95% CI 0.97 to 1.03) (Analysis 3.1). No differences were
observed between statin and control with the number of partic-
ipants stopping statin treatment due to adverse events and those
admitted to hospital for an adverse event, though heterogeneity
was observed (Analysis 3.2; Analysis 3.3).
Cancer: 2255/38,739 (5.8%) participants in 11 trials developed
cancer (Analysis 3.4). There was no evidence of any excess risk of
cancers with a pooled estimate of RR 1.01 (95% CI 0.93 to 1.10)
and no heterogeneity.
Myalgia and rhabdomyolysis: 3551/37,939 participants in nine
trials developed myalgia, but there was no evidence of excess risk
with a pooled estimate of 1.03 (95% CI 0.97 to 1.09] with some
heterogeneity (I2 = 41%) (Analysis 3.5). Rhabdomyolysis was very
rare, affecting three of 19,410 participants on statins in six trials
reporting this outcome but with no evidence of any excess risk on
statins: RR 1.00 (95% CI 0.23 to 4.38) (Analysis 3.6).The Heart
Protection Study outcomes for rhabdomyolysis were five cases in
those on statins and three cases among controls, but these find-
ings were not broken down by primary and secondary prevention.
Adding these additional events to the estimate above gives RR 1.31
(95% CI 0.47 to 3.62).
Type 2 diabetes: reporting of new occurrences of type 2 dia-
betes was confined to only two trials, AFCAPS/TexCAPS 1998
and JUPITER 2008. Overall, 342/12,205 (2.8%) participants on
statins developed diabetes compared with 290/12202 (2.4%) par-
ticipants on control or placebo, with a relative risk of developing
diabetes of 1.18 (95% CI 1.01 to 1.39). This excess risk of dia-
betes was driven by the JUPITER trial, which used higher statin
doses than the AFACPS/TexCAPS trial, which showed no effect
on diabetes incidence (Analysis 3.7).
Haemorrhagic stroke: only two trials reported haemorrhagic
stroke outcomes which occurred in 45/25634 (0.2%) participants
with a RR of 0.97 (95% CI 0.54 to 1.75) (Analysis 3.8).
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Other adverse events: weak evidence was found for an increased
risk of liver enzyme elevations (10 studies) RR 1.16 (95% CI 0.87
to 1.54) (Analysis 3.9), renal dysfunction (four studies) RR 1.11
(95% CI 0.99 to 1.26) (Analysis 3.10), and arthritis (two studies)
RR 1.20 (95% CI 0.82 to 1.75) (Analysis 3.11).
Treatment compliance
Of the eight trials that reported treatment compliance there was
no difference between the two groups (Analysis 4.1). In the statin
group 77% participants and 70% in the placebo group complied
with treatment; RR 1.08 (0.98 to 1.18).
Costs
Four trials reported on costs. WOSCOPS found that the use of
statin yielded substantial health benefits at a cost which was not
prohibitive: an undiscounted gain of 2460 years of life at a cost of
£8,121 per life year gained (WOSCOPS). In the JUPITER trial,
the authors estimated that rosuvastatin therapy was cost-effec-
tive, using a willingness-to-pay threshold of £31,882/QALY, statin
therapy had a cost-effectiveness of £25,796/QALY for CHD and
stroke prevention. (JUPITER 2008-Ohsfeldt 2010) The authors
of CARDS estimated the cost of managing CVD events would be
lower after five years for patients treated with atorvastatin com-
pared with those on placebo. The cost-effectiveness of atorvastatin
10 mg/day would be £87,525/QALY at five years, with an incre-
mental cost of £2,320/QALY at 10 years. (CARDS 2008-Ramsay
2008)
Patient quality of life
There were no reliable data on patient quality of life reported by
trials. CELL A+B provided limited data on quality of life, sug-
gesting that the intervention of lifestyle advise plus pravastatin re-
duced stress and sleeping problems.
Sensitivity analysis
We were unable to locate any unpublished studies. As the study
quality was overall rated as good, for the update we confined our
sensitivity analysis to comparing studies that were stopped early
and followed a protocol and to comparing large and small studies
for total mortality and total CHD events. These analyses indicated
no change in the overall results in early stopping of trials and for
study size for either outcome (Analysis 5.1; Analysis 5.2 Analysis
5.3; Analysis 5.4).
Excluding the five trials that included up to 10% participants with
clinical evidence of CVD (none of the trials published the sub-
group without any evidence of CVD) demonstrates very similar
findings: total mortality RR 0.80 (95% CI 0.70 to 0.91) versus
RR 0.86 (0.79 to 0.94) in all trials; total CHD events RR 0.68
(0.59 to 0.77) versus 0.73 (0.67 to 0.80) in all trials; adverse events
RR 0.99 (0.96 to 1.02) versus 1.00 (0.97 to 1.03) in all trials.
D I S C U S S I O N
The trials included in this systematic review showed reductions in
all-cause mortality, composite cardiovascular disease (CVD) end-
points, fatal and non-fatal CVD events considered separately, to-
tal and low density lipoprotein (LDL) cholesterol, and revascu-
larisations. These findings were associated with falls in total and
LDL cholesterol in all trials reporting these outcomes. No excess
of combined adverse events, cancers, myopathy, rhabdomyolysis,
haemorrhagic stroke, liver enzyme elevation, renal dysfunction
and arthritis were found, although not all trials reported fully on
adverse events. An increased risk of incident diabetes was found in
the two trials reporting this outcome. There was limited evidence
to suggest that the use of statins for primary prevention may be
cost-effective. However, in light of new evidence derived from the
CTT Collaboration on primary prevention, there is a need to up-
date existing cost-effective analysis. Patient perceived quality of
life was reported in only one trial, which showed limited benefit.
Sensitivity analysis suggested that early stopping of trials and size
of trial did not influence the overall results.
Although the trials intended to recruit only people without ev-
idence of CVD, some trials did include some participants with
CVD. Rather than exclude such trials, we set an arbitrary thresh-
old of 10% to avoid any major influence of effects of treatment
on those with existing CVD. A sensitivity analysis, excluding the
five trials that had up to 10% participants with clinical evidence of
CVD at baseline, showed very little difference between effect sizes
compared with all the trials included in this review. Our findings
concur with previous systematic reviews (Brugts 2009; Ebrahim
1999; NICE 2006). However, previous systematic reviews have
included trials where more than 10% of participants had a previ-
ous history of CVD which is reflected in their higher baseline all-
cause mortality event rates which were 1.4 per 100 person years
at risk (NICE 2006) and 1.7 per 100 person years (Brugts 2009)
compared with 1.0 per 100 person years in this review.
The CTT Collaboration has published analyses focusing on the
comparison between high and low doses of statins which demon-
strate that more intensive treatment lowers LDL cholesterol more,
resulting in greater benefits (CTT Collaboration 2010) with no
excess risk of non-vascular mortality. However, a increase in the
risk ofmyopathy and rhabdomyolysis in people treatedwith statins
is confirmed, particularly among those treated with higher rather
than lower doses statins (Armitage 2007). Strong evidence of the
absence of any adverse effects on cancer risk is also confirmed by a
further CTT Collaboration report (CTT Collaboration 2012b).
Our estimates of effects on CVD outcomes and on all-cause mor-
tality on statins are in line with the recent CTT Collaboration re-
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port (CTT Collaboration 2012a). The major finding of this new
report is the benefits from statins at low levels of CVD risk: six
and 15 major vascular events would be avoided per 1000 people
treated for five years in the two lowest baseline risk categories (<
5% five-year risk, RR 0·57 (0·36 to 0·89) and 5% to 10% five-year
risk RR 0·61 (0·50 to 0·74)) respectively (Figure 1, CTT report),
giving NNT values of 167 and 67 respectively. These NNTs are
well within the range considered worthwhile in primary preven-
tion (e.g. for treatment of hypertension).
The individual patient data analyses conducted by the CTT Col-
laboration counter concerns about the interpretation of the ev-
idence of statins for primary prevention. First, the use of com-
posite endpoints derived from different CVD outcomes is over-
come since there is sufficient power to demonstrate benefits for
individual CVD outcomes. Second, additional data on outcomes
are available for most trials, which reduces any effect of selective
reporting of outcomes. Third, similar benefits of statins were seen
in trials that stopped early and in those running their planned
course. Fourth, concerns about effects in low-risk groups, partic-
ularly women, are now demonstrated to be similar to those in
other trial participants. Fifth, the benefits of statins outweigh any
risks of serious adverse effects since no excess of cancers was found
and all-cause mortality was lower in those on statins. Thus, ear-
lier claims that statins provide no overall benefit in primary pre-
vention in terms of all-cause mortality (Therapeutics Letter 2003;
Therapeutics Letter 2010; Ray 2010) can no longer be substanti-
ated.
Haemorrhagic strokemay be increased by use of statins with an an-
nual excess risk of 0.5 per 1000people treated over five years per 1·0
mmol/L LDL cholesterol reduction reported by the CTT Collab-
oration. However, overall stroke events were reduced, indicating a
net benefit. This might not be the case in Asian populations where
haemorrhagic stroke is more common than ischaemic stroke, and
where evidence of association between low blood cholesterol and
haemorrhagic stroke has been reported (Ebrahim 2006).
Our review, with sparse data, found an increased risk of type 2
diabetes in those treated with statins: RR 1.18 (95% CI 1.01 to
1.39), which is greater than the that found in a more compre-
hensive meta-analysis using both published and unpublished data
from 13 trials (both primary and secondary prevention) which re-
ported a relative risk of 1·09; 95% CI 1·02 to 1·17, with a num-
ber needed to harm of 255 people treated for four years to result
in one case of diabetes (Preiss 2011; Sattar 2010). This increased
risk of diabetes appears to be related to baseline fasting glucose
levels and metabolic syndrome among participants randomised
to statins (Waters 2011). It can be argued that the overall small
proportion of people who develop diabetes when treated with a
statin is outweighed by the benefits of statins (CTT Collaboration
2012a). However, in the context of primary prevention, patients
may expect not to be harmed in any way by ’preventive’ treat-
ments. Patient view points of such trade-offs remain to be assessed
and will be important in determining wider use of statins (Smeeth
2012).
All but one of the trials had some form of pharmaceutical industry
sponsorship. It is now established that published pharmaceutical
industry-sponsored trials are more likely than non-industry-spon-
sored trials to report results and conclusions that favour drug over
placebo due to biased reporting and/or interpretation of trial re-
sults (Als-Nielsen 2003). The reporting of adverse events in these
trials is generally poor, with failure to provide details of severity
and type of adverse events or to report on health-related quality
of life. However, it seems unlikely that any major life-threatening
hazards associated with statin use exist. Potential non-fatal but se-
rious hazards of long-term statin use have not been assessed in trials
(e.g. possible cognitive impairments suggested by one small trial:
Muldoon 2000).We have focused on adverse events arising in ran-
domised trial populations but these cannot adequately assess rare
hazards, such as rhabdomyolysis. Large observational databases are
useful for detecting rare hazards associated with use of statins but
a causal attribution is more difficult to establish (Hippsley-Cox
2010; Smeeth 2008).
Our previous conclusion urging caution in the use of statins in
people at low risk of cardiovascular events is no longer tenable
in light of the CTT Collaboration findings. Several issues remain
to be considered before widespread use of statins could be rec-
ommended in people at low risk (Ebrahim 2012; Smeeth 2012).
These include: i) the feasibility and desirability of having to treat
the majority of people over the age of 50 with a statin; ii) the cost-
effectiveness of such a strategy using a conventional healthcare de-
livery system; iii) diversion of attention from achieving coverage
in people at high risk of events; iv) use of alternative public health
strategies to lower blood cholesterol; v) the views of patients on
life-long drug therapy; and vi) limited evidence on less serious but
nonetheless potentially important adverse effects and quality of
life.
The National Institute for Health & Clinical Excellence UK
(NICE) has provided some cost-effectiveness estimates based on
data to 2005 and conclude that an annual risk of a CHD event
ranging from 3% to 0.5%, the ranges of cost per quality adjusted
life year gained (QALY) gained were £10,000 to £31,000 at age
45 years, £13,000 to £40,000 at age 55 years using older generic
statins (NICE 2006). Their guidance is to use statins “... as part
of the management strategy for the primary prevention of CVD
for adults who have a 20% or greater 10-year risk of developing
CVD.” Evidence supporting the use of statins as part of an overall
strategy of identification of people at high risk of CVD events and
lowering blood pressure and blood cholesterol has been produced
for low- and middle-income countries (Lim 2007) and is now
part of World Health Organization’s policy for CVD prevention
(WHO 2008b).
Low cost generic statins are now widely available and recent cost-
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effectiveness studies show that statins are cost-saving in the USA
even in people at low levels of predicted CHD risk. To gain maxi-
mal impact from using statins, 64 million people in the USA (just
under half of the over 35 year old population) would need to be
put on treatment at a cost of US$2,800 per QALY gained (Lazar
2011). These cost-effectiveness estimates are likely to be better
for more potent statins and in lower cost health services.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The totality of evidence now supports the benefits of statins for
primary prevention. The individual patient data meta-analyses
now provide strong evidence to support their use in people at low
risk of cardiovascular disease. Further cost-effectiveness analyses
are now needed to guide widening their use to these low risk
groups.
Implications for research
In addition to the cost-effectiveness analyses referred to above, it
will be useful to study the effects of public health interventions that
attempt to alter diet and physical activity patterns and compare
their effects with statins in robust randomised trials given recent
evidence of large independent survival benefits of physical fitness in
those taking statins in a large prospective cohort study (Kokkinos
2012). Relevant interventions might include nutrition education,
exercise prescription, physical education curriculums that may be
effective in changing lifestyle behaviours. (Jepson 2000) Studies of
patient experiences and views on long-term use of statins are also
needed to improve adherence to treatment. It is likely that further
trials will be conducted in younger adults with adverse risk factor
profiles which are associated with higher lifetime CVD risk (Berry
2012) and also in children (de Ferranti 2008). It is important that
these trials examine comprehensively potential adverse effects of
statins and quality of life, reporting on them in an unbiased way.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
ACAPS 1994
Methods Randomised trial 4 x 4 factorial.
Participants 919 participants based in the USA aged 40 - 79 (mean age of 62); 52% men. None with
any clinical evidence of CVD
Interventions 20 mg lovastatin + 1 mg warfarin versus placebo followed up for 34 months
Outcomes Carotid atherosclerosis, cholesterol, fatal + non-fatal CHD events, stroke
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Blocked randomisation stratified by centre
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Carers and patients were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT, no drop-outs reported
Selective reporting (reporting bias) Low risk
Other bias Unclear risk Funded by pharmaceutical industry
Adult Japanese MEGA Study
Methods Randomised trial.
Participants 7832 participants with hypercholesterolaemia based in Japan aged 40-70 (mean age 59)
; 32% men. None with any clinical evidence of CVD
Interventions 10-20 mg pravastatin versus placebo; all participants got advice on diet; follow-up 5
years
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Adult Japanese MEGA Study (Continued)
Outcomes Primary: composite of major CVD events, sudden cardiac death, angina and revascular-
isation. Single outcomes included: all-cause mortality, total CVD events, fatal and non-
fatal MI, stroke and TIA events, sudden cardiac death, angina and revascularisation,
cholesterol, adverse events
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerised randomisation by permuted block method.
Allocation concealment (selection bias) Low risk Central laboratory.
Blinding (performance bias and detection
bias)
All outcomes
High risk Single blinded, endpoint committee was blinded only because
investigators stated that placebo-controlled trials are regarded
with suspicion by Japanese participants
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT used 2% dropped out.
Selective reporting (reporting bias) High risk Not all adverse events reported. We wrote to the authors ask-
ing for clarity regarding data on serious events. The authors re-
sponded saying they were unable to send the data
Other bias Low risk Groups were comparable at baseline and includes all the major
prognostic factors
Funded by pharmaceutical industry.
AFCAPS/TexCAPS 1998
Methods Randomised trial.
Participants 6606 participants in Texas, USA; mean age 58; 57.5% men; 89% Caucasian. None with
any clinical evidence of CVD
Interventions 20-40 mg lovastatin compared with placebo; follow-up for 5.2 years; all participants
received advice on diet
Outcomes Primary: composite of fatal and non-fatal MI and fatal CHD events. Single outcomes
included: all-cause mortality, fatal and non-fatal CVD + stroke events, heart failure and
adverse events
Notes Trial was stopped prematurely. To be terminated when 320 participants had experienced
primary outcome event. Stopped when 267 had done at 5.2 years
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AFCAPS/TexCAPS 1998 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind: participants and personnel
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT used no drop-outs reported
Selective reporting (reporting bias) Low risk Other than results for cholesterol
Other bias Unclear risk Funded by pharmaceutical industry
ASPEN 2006
Methods Randomised trial.
Participants 2410 participants with type 2 diabetes based in 16 developed countries with mean age
60; 62.5% men; 84% Caucasian. < 10% with clinical evidence of CVD
Interventions 10 mg atorvastatin versus placebo; follow-up of 2.4 years (for primary prevention par-
ticipants)
Outcomes Primary: composite of fatal MI, stroke, sudden cardiac death, heart failure, CVD death.
Single outcomes included: non-fatal or silent MI + stroke, revascularisation, resuscitated
cardiac arrest, TIA, unstable angina, peripheral arterial disease, Ischaemic heart failure
and adverse events
Notes Primary prevention participants recruited 2-3 years into the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
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ASPEN 2006 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind: participants and outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT used 22% drop-outs reported
Selective reporting (reporting bias) Low risk Other than not providing results on adverse events for primary
prevention group
Other bias Unclear risk Funded by pharmaceutical industry
Bone 2007
Methods Randomised control trial.
Participants 626 Post-menopausal women aged 40-75 years with dyslipidaemia and no history of
CHD or diabetes. None with any clinical evidence of CVD
Interventions Atorvastatin (10/20/40/80 mg/day) with matching placebo. All patients were instructed
to be on NCEP ATP III diet
Outcomes Primary: Percentage change in lumbar spine bone marrow density Seconday: Percentage
change in femoral neck etc BMD by DXA. other; adverse events
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated pseudo random code
Allocation concealment (selection bias) Low risk Random permuted blocks
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk States double blind but only reported that participants were
blinded to interventions
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT used, 5% dropped out.
Selective reporting (reporting bias) Low risk All outcomes reported.
Other bias Unclear risk Funded by pharmaceutical industry
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CAIUS 1996
Methods Randomised trial.
Participants 305 participants with hypercholesterolaemia based in Italy with mean age 55; 53%men.
None with any clinical evidence of CVD
Interventions 40 mg pravastatin versus placebo; follow-up of three years.
Outcomes Slope of carotid artery, fatal and non-fatal MI, angina, revascularisations, cholesterol and
adverse events
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Independent co-ordinating centre controlled allocation
Allocation concealment (selection bias) Low risk Independent co-ordinating centre controlled allocation
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Double-blind: participants and personnel
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT used, 13% dropped out
Selective reporting (reporting bias) Low risk
Other bias Unclear risk Funded by pharmaceutical industry
CARDS 2008
Methods Randomised control trial.
Participants 2838 participants with diabetes based in UK and Ireland aged 40-75 years (mean 61.7)
; 68% men; 94.5% Caucasian. None with any clinical evidence of CVD
Interventions 10 mg atorvastatin, all patients were given counselling on cessation of smoking; follow
up of 3.9-4 years
Outcomes Primary: composite of fatal and non-fatal MI, acute CHD death, resuscitated cardiac
arrest. Single outcomes included: all-cause mortality, fatal and non-fatal or silent MI
+ stroke, revascularisation, resuscitated cardiac arrest, total CVD events, adverse events
and cholesterol
Notes Trial stopped prematurely due to large beneficial treatment effect
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CARDS 2008 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation code
Allocation concealment (selection bias) Low risk Staff and patients unaware of computer-generated ran-
domisation code
Blinding (performance bias and detection
bias)
All outcomes
Low risk Triple-blind: participants, personnel and outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT used, no drop-outs reported
Selective reporting (reporting bias) Low risk
Other bias Unclear risk Funded by pharmaceutical industry
CELL A 1996
Methods Randomised trial; 2 x 3 factorial design.
Participants 228 participants with hyperlipidaemia based in Sweden with a mean age of 49; 85%
men, <10% had clinical evidence of CVD
Interventions 10-40 mg pravastatin plus intensive dietary advice versus placebo; follow-up for 18
months
Outcomes Fatal MI, cholesterol, quality of life.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Not described
Allocation concealment (selection bias) Low risk Randomisation performed separately for
each centre with numbers allocated to inter-
vention and control groups
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CELL A 1996 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind: participants and personnel
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT used, 14.5% dropped out
Selective reporting (reporting bias) High risk Adverse events rates not provided for each
group
Other bias Unclear risk Funded by pharmaceutical industry
CELL B 1996
Methods Randomised trial; 2 x 3 factorial design.
Participants 227 participants with hyperlipidaemia based in Sweden with a mean age of 49; 85%
men, <10% had clinical evidence of CVD
Interventions 10-40 mg pravastatin plus dietary advice versus placebo; follow-up for 18 months
Outcomes Fatal MI, cholesterol, quality of life.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Not described
Allocation concealment (selection bias) Low risk Randomisation performed separately for
each centre with numbers allocated to inter-
vention and control groups
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind: participants and personnel
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT used, 6% dropped out
Selective reporting (reporting bias) Unclear risk CVD and adverse events rates not provided
for each group
Other bias Unclear risk Funded by pharmaceutical industry
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CERDIA 2004
Methods Parallel group randomised control trial.
Participants 250 patients with type 2 Diabetes aged 30-80 years. None with any clinical evidence of
CVD
Interventions 0.4 mg of Cerivastatin until 08/2001 then Simvastain 20 mg.
Outcomes Primary outcome: Change in mean common carotid intima media thickness (IMT) after
24 months of intervention. Secondary outcomes: Changes in Mean + maximum IMT
at 24 months, CVD events, amputation due to atherosclerotic disease, serum levels of
LDL and total cholesterol
Notes In August 2001, Cerivstatin was withdrawn from market.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Predetermined computer-generated
randomisation sequence in block of 10
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk States double blind but only reported that
participants were blinded to interventions
Incomplete outcome data (attrition bias)
All outcomes
High risk ITT not used, 27% dropped out.
Selective reporting (reporting bias) Low risk States double blind but unclear who was
blinded.
Other bias Unclear risk Comparable at baseline, including all major
prognostic group however its unclear if it was
valid and reliable method to determine out-
comes
Funded by pharmaceutical industry.
Derosa 2003
Methods Randomised trial.
Participants 47 participants with hypercholesterolaemia based in Italy with a mean age of 51; 46%
men. None with any clinical evidence of CVD
Interventions 80 mg fluvastatin versus placebo; all participants were given advice on diet and exercise
; follow-up for one year
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Derosa 2003 (Continued)
Outcomes Adverse events, cholesterol.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Envelopes containing randomisation codes prepared by statisti-
cian
Allocation concealment (selection bias) Low risk Allocation code could only be identified by statistician and per-
son responsible for statistical analysis
Blinding (performance bias and detection
bias)
All outcomes
Low risk Single blind: participants
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT used, no drop-outs reported
Selective reporting (reporting bias) Low risk
Other bias Unclear risk Funded by pharmaceutical industry
HYRIM 2007
Methods Randomised trial 2 x 2 factorial design.
Participants 287 men with hypertension based in Norway aged 40-75 years (mean age 57). None
with any clinical evidence of CVD
Interventions 40 mg fluvastatin; follow-up four years.
Outcomes Primary: composite of fatal and non-fatal MI, + stroke, angina, sudden CHD death,
TIA and heart failure. MACE: composite of cardiac death, fatal and non-fatal MI and
revascularisation. Single outcomes included: adverse events, cholesterol
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
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HYRIM 2007 (Continued)
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind: participants and personnel
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described and no drop-outs reported
Selective reporting (reporting bias) Low risk Mostly but not for adverse events and choles-
terol level at baseline and at 4-year follow-up
not provided
Other bias Unclear risk Groups comparable at baseline, including all
major prognostic factors, structured interview
for outcomes and side effects confirmed by
independent expert committee
Funded by pharmaceutical industry.
JUPITER 2008
Methods Randomised control trial.
Participants 17,802 participants (intervention:8901, control 8901) > 50 years. None with any clinical
evidence of CVD
Interventions Rosuvastatin 20 mg daily.
Outcomes First occurrence of major cardiovascular event, revascularisation, hospital admission for
angina, MI, stroke, all-cause death, CVD death and adverse events
Notes Stopped early with a follow-up of 1.9 years.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation done in block of 4, use of Interactive voice
response system-generated allocation sequence
Allocation concealment (selection bias) Low risk Stratified according to the centre
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind, participants and outcomes assessed by end
point committee
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT used, no drop-outs reported
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JUPITER 2008 (Continued)
Selective reporting (reporting bias) Low risk There was limited data on LDL and TC at the end of trial
Other bias High risk Groups comparable at baseline, including all major prog-
nostic factors, structured interview assessing outcomes and
adverse effects confirmed by independent expert commit-
tee. Trial was stopped early with a follow-up of 1.9 years.
Funded by pharmaceutical industry
KAPS 1995
Methods Randomised trial.
Participants 447 men based in Finland aged 44-65 years (mean 57). < 10% with clinical evidence of
CVD
Interventions 40 mg pravastatin versus placebo; follow-up of 3 years.
Outcomes Carotid atherosclerotic progression, total mortality, fatal and non-fatal MI events, stroke,
adverse events, cholesterol, other cardiac death, revascularisations, non cardiac death and
heart failure
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Biostatistician prepared randomisation scheme
Allocation concealment (selection bias) Low risk Tablets were masked by pharmaceutical company
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind: participants and personnel
Incomplete outcome data (attrition bias)
All outcomes
High risk ITT was not used, 17% patients dropped out
Selective reporting (reporting bias) Low risk
Other bias Unclear risk Funded by pharmaceutical industry
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METEOR 2010
Methods Randomised control trial.
Participants 984 asymptomatic individuals with a mean age of 57 years. None with any clinical
evidence of CVD
Interventions Rosuvastatin 40 mg/ day.
Outcomes Primary:Meanof 12Carotid Intimamedia (CIMT) thicknessmeasurements. Secondary:
CIMTmeasurements of left and right common carotid artery. Other relevant outcomes:
adverse events, cholesterol levels
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation in block of 7 (5 to intervention and 5 to
control)
Allocation concealment (selection bias) Low risk Blinded study medication
Blinding (performance bias and detection
bias)
All outcomes
Low risk Blinding both to participants and personnel.
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT used 25-6% dropped out.
Selective reporting (reporting bias) Low risk
Other bias Unclear risk Funded by pharmaceutical industry
MRC/BHF Heart Protection
Methods Randomised trial (2 x 2 factorial design).
Participants 3982 patients with no prior CHDwith diabetes mellitus as a subset of 20,536 UK adults
aged 40-80 years
Interventions 40 mg simvastatin compared with placebo, follow-up 5.3 years for all participants
Outcomes Composite of coronary and vascular events, stroke, revascularisations
Notes
Risk of bias
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MRC/BHF Heart Protection (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Not described
Allocation concealment (selection bias) Low risk Central telephone system used
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind: participants and outcome as-
sessors
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described
Selective reporting (reporting bias) High risk Only CVD event results provided for this
subgroup
Other bias Unclear risk Funded by pharmaceutical industry.
PHYLLIS 2004
Methods Randomised trial 4 x 4 factorial.
Participants 253 men and women aged 45-70 (mean age 58) with hypertension, hypercholestero-
laemia and asymptomatic carotid atherosclerosis based in Italy. None with any clinical
evidence of CVD
Interventions 25 mg hydrochlorothiazide + 40 mg pravastatin followed up for 2.6 years
Outcomes Primary outcomes: carotid atherosclerosis. Secondary outcomes: non-fatal MI, CVD
death, stroke, cholesterol and cancer
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was computer-generated in blocks of
4
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
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PHYLLIS 2004 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT used, 20% drop-outs reported
Selective reporting (reporting bias) Low risk
Other bias Unclear risk Funded by pharmaceutical industry
PREVEND IT 2004
Methods Randomised trial 2 x 2 factorial design.
Participants 864 participants with microalbuminuria based in Holland aged 28-75 years (mean age
51); 64.5% men; 96% Caucasian. < 10% with clinical evidence of CVD
Interventions 40 mg pravastatin versus placebo; follow-up 3.8 years.
Outcomes Primary outcome: composite of fatal and non-fatal CVD events. Single outcomes in-
cluded fatal CVD events, stroke, heart failure, non-fatal MI and cholesterol
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was computer-generated.
Allocation concealment (selection bias) Low risk Participants randomised were allocated to a
treatment number
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk ITT used but confined to CVD events, 6%
dropped out
Selective reporting (reporting bias) Low risk
Other bias Unclear risk Funded by pharmaceutical industry
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WOSCOPS
Methods Randomised trial.
Participants 6595 men with hypercholesterolaemia based in Scotland aged 45-64 (mean age 55). <
10% with clinical evidence of CVD
Interventions 40 mg pravastatin versus placebo; follow-up 4.9 years.
Outcomes Primary outcome: composite of non-fatalMI andCHDdeath. Single outcomes included
total mortality, fatal CVD events, cholesterol, revascularisations, non-fatal MI and CHD
death and adverse events
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Blocks of random numbers and treatment assigned randomly
Allocation concealment (selection bias) Low risk All trial personnel remained unaware of the participant’s treat-
ment assignment throughout the study
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind: participants and personnel
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT used, 30% drop-outs reported
Selective reporting (reporting bias) Low risk
Other bias Unclear risk Funded by pharmaceutical industry
BMD: bone mineral density
CHD: coronary heart disease
CIMT: carotid intima media thickness
CVD: cardiovascular disease
DXA: Dual-energy X-ray absorptiometry
ITT: intention-to-treat
LDL: low density lipoprotein
MI: myocardial infarction
TC: total cholesterol
TIA: transient ischaemic attack
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Agewall 2006 Treatment length was less than a year
ALLHAT-LLT 2002 15% patients had history of CVD
Ames 2011 No relevant outcomes reported
Anderson 1993 No placebo - statin + antioxidant versus statin + antioxidant
ASCOT-LLA 2003 18% patients had history of CVD
ASTRONOMER 2010 Study is not a primary prevention
Bak 1998 Treatment length was less than a year
BCAPS 2001 11% patients had history of CVD
Boccuzzi 1991 Not a RCT - all participants were given Simvastatin
Branchi 1995 Control Group was not randomised
Byington 1993 Secondary prevention
CASHMERE 2007 Treatment length was less than a year
Cassader 1993 Treatment length was less than a year
CHALLENGER Patients with CHD were included in study
Chan 1996 Treatment length was less than a year
Chuengsamarn 2010 Study is not a RCT
CLIP 2002 Not a RCT - All participants were given Pravastatin
Cowan 2010 Follow-up duration was inadequate
Coylewright 2008 Secondary prevention
CRISP 1994 Treatment length was less than a year
CURVES 1998 No placebo - statin versus statin
Dangas 1999 Treatment length was less than a year
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(Continued)
Davidson 1997 No placebo - statin versus statin
Duffy 2001 Treatment length was less than a year
Egashira 1994 Not a RCT - All participants were given Pravastatin
Eriksson 1998 No control group - Pravastatin vs. Cholestyramine
EXCEL 1990 Treatment length was less than a year
Faergeman 2009 Comparison of two statins/doses
FAST 2002 Over 40% had CVD and over 14% had CHD
Ferrari 1993 Treatment length was less than a year
Gentile 2000 Treatment length was only 24 weeks
Glasser 1996 Length of treatment was only 12 weeks
Gomez-Garcia 2007 Follow-up period was less than a year
Guisasola 2009 Study is not a RCT
Hokuriku NK-104 Study 02 Not a RCT - All participants were given intravasating
Hongo 2010 No placebo control group
Hufnagel 2000 Treatment length was less than a year
Italian Family Physician Not a RCT - open-labelled
J-LIT 2007 Study is not a RCT
Jardine 2006 Outcomes provided were aggregated. Unable to ascertain actual numbers for cardiac death and my-
ocardial infarction
JART 2011 Comparison was between two types of statin
JELIS 2009 No placebo/control group and study was a secondary prevention
Jones 1991 Treatment length was less than a year
Kappelle 2009 Treatment length was less than a year
KLIS 2000 Not randomised
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(Continued)
Kojima 2010 Secondary prevention
Lemaitre 2002 Cohort study
Lin 2010 No relevant outcomes reported.
LIPID 2010 Secondary prevention
Mareev 2008 Previous history of cardiovascular disease in most patients
McDermott 2003 Participants were not randomised to statins or no statins
Mizuguchi 2008 Study outcomes are not relevant to current review.
Mohler 2003 Patients recruited had peripheral arterial disease
Mok 2009 Secondary prevention
Muldoon 1997 Treatment length is only six months
Nephrotic Syndrome Study Treatment length was less than a year
Ohta 2000 Treatment length was less than a year
Oi 1997 No placebo or control group
Olzowy 2007 Outcomes of the study are not relevant to review.
Ormiston 2003 Not a RCT - all participants were given statins
Pavia 2000 Intervention included Amlodipine
Pitt 1999 No placebo - statins versus angioplasty
POSCH 1990 Statins were not used
Pravastatin Multi 1993 Treatment length was less than a year
PROSPER 2002 More than 10% of the participants had CVD
Safaei 2007 Study is not a RCT
SANDS 2008 Comparison of two different treatment algorithms which included statins
Schmermund 2006 Comparision of 10 mg vs 80 mg of statin.
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(Continued)
Sen 2000 Treatment length was less than a year
Sprecher 1994 Treatment length was less than a year
Stein 1997 Treatment length was less than a year
Su 2000 Treatment length was less than a year
Tanaka 2001 Treatment length was less than a year
Tarin 2010 Secondary prevention
Teixeira 2011 No relevant outcomes
Tekin 2008 Not randomised
Thomas 1993 Treatment length was less than a year
Thrombosis Prevention Statins were not used
Togha 2009 Patients had a chronic disease.
Tran 2007 The data are based on inadequate length of treatment
Wallace 2003 Treatment length was less than a year
Wu 2007 No comparison group
Yu-An 1998 Treatment length was less than one year
Zachoval 2000 Comparison of two statins
CHD: coronary heart disease
CVD: cardiovascular disease
RCT: randomised controlled trial
Characteristics of studies awaiting assessment [ordered by study ID]
Babes 2010
Methods RCT
Participants Young adults
Interventions Statin
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Babes 2010 (Continued)
Outcomes Endothelial dysfunction
Notes We wrote on three separate occasions to the authors for further information on this study and did not receive a
response
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Mortality and Morbidity
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total Mortality 13 48060 Odds Ratio (M-H, Fixed, 95% CI) 0.86 [0.79, 0.94]
2 Total Number of CHD Events 14 48049 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.67, 0.80]
3 Number of Fatal CHD Events 10 46094 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.70, 0.96]
4 Number of Non-fatal CHD
Events
11 40977 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.59, 0.76]
5 Total Number of CVD Events 9 23805 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.70, 0.81]
6 Number of Fatal CVD Events 5 34012 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.72, 0.96]
7 Number of Non-fatal CVD
Events
2 8696 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.62, 0.96]
8 Total Number of Stroke Events 10 40295 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.68, 0.89]
9 Number of Fatal Stroke Events 3 27238 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.18, 2.23]
10 Number of Non-fatal Stroke
Events
5 28097 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.58, 0.83]
11 Total Number of Fatal and
Non-fatal CHD, CVD and
Stroke Events
4 35254 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.58, 0.73]
12 Number of Study
Participants who underwent
Revascularisation
7 42403 Risk Ratio (M-H, Fixed, 95% CI) 0.62 [0.54, 0.72]
Comparison 2. Lipids (mmol/L)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total Cholesterol (mmol/L) 14 34122 Mean Difference (IV, Random, 95% CI) -1.05 [-1.35, -0.76]
2 LDL Cholesterol (mmol/L) 16 41380 Mean Difference (IV, Random, 95% CI) -1.00 [-1.16, -0.85]
Comparison 3. Adverse Events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of study participants
who had adverse events
12 40716 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.97, 1.03]
2 Number of study participants
who stopped treatment due to
adverse events
9 21642 Odds Ratio (M-H, Random, 95% CI) 0.86 [0.65, 1.12]
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3 Number of study participants
who were admitted to hospital
2 19707 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.38, 1.41]
4 Number of study participants
who developed cancer
11 38739 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.93, 1.10]
5 Number of study participants
who developed myalgia or
muscle pain
9 37938 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.97, 1.09]
6 Number of study participants
who developed rhabdomyolysis
6 38468 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.23, 4.38]
7 Number of study participants
who developed diabetes
2 24407 Odds Ratio (M-H, Fixed, 95% CI) 1.18 [1.01, 1.39]
8 Number of study participants
who developed haemorrhagic
stroke
2 25634 Odds Ratio (M-H, Fixed, 95% CI) 0.97 [0.54, 1.75]
9 Number of study participants
who had elevated liver enzymes
10 40094 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.87, 1.54]
10 Number of study participants
who developed renal disorder
4 27804 Odds Ratio (M-H, Fixed, 95% CI) 1.11 [0.99, 1.26]
11 Number of study participants
who developed arthritis
2 7586 Odds Ratio (M-H, Random, 95% CI) 1.20 [0.82, 1.75]
Comparison 4. Treatment Compliance
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Treatment Compliance 8 41712 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.98, 1.18]
Comparison 5. Sensitivity Analysis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Early stopping of trials and total
mortality
11 46811 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.74, 0.92]
1.1 trials stopped early 3 27245 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.72, 0.96]
1.2 trials with no early stop 8 19566 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.69, 0.98]
2 Early stopping of trials and total
CHD events
14 48066 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.67, 0.80]
2.1 trials stopped early 3 27265 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.58, 0.79]
2.2 trials with no early stop 11 20801 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.69, 0.84]
3 Study Size for total Mortality 11 46811 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.74, 0.92]
3.1 Over 1000 participants 6 43754 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.74, 0.92]
3.2 Under 1000 participants 5 3057 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.50, 1.82]
4 Study Size for total CHD events 14 48066 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.67, 0.80]
4.1 Over 1000 participants 6 43597 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.67, 0.80]
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4.2 Under 1000 participants 8 4469 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.39, 0.90]
Analysis 1.1. Comparison 1 Mortality and Morbidity, Outcome 1 Total Mortality.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 1 Mortality and Morbidity
Outcome: 1 Total Mortality
Study or subgroup Statin Therapy Group
Usual Care
or Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ACAPS 1994 1/460 8/459 0.12 [ 0.02, 0.99 ]
Adult Japanese MEGA Study 55/3866 79/3966 0.71 [ 0.50, 1.00 ]
AFCAPS/TexCAPS 1998 80/3304 77/3301 1.04 [ 0.76, 1.43 ]
ASPEN 2006 44/959 41/946 1.06 [ 0.69, 1.64 ]
Bone 2007 0/485 0/119 0.0 [ 0.0, 0.0 ]
CARDS 2008 61/1428 82/1410 0.72 [ 0.51, 1.02 ]
CERDIA 2004 3/103 4/79 0.56 [ 0.12, 2.59 ]
JUPITER 2008 198/8901 247/8901 0.80 [ 0.66, 0.96 ]
KAPS 1995 4/214 3/212 1.33 [ 0.29, 6.00 ]
METEOR 2010 1/700 0/281 1.21 [ 0.05, 29.72 ]
PHYLLIS 2004 1/253 0/254 3.02 [ 0.12, 74.58 ]
PREVEND IT 2004 10/433 8/431 1.25 [ 0.49, 3.20 ]
WOSCOPS 619/3302 674/3293 0.90 [ 0.79, 1.01 ]
Total (95% CI) 24408 23652 0.86 [ 0.79, 0.94 ]
Total events: 1077 (Statin Therapy Group), 1223 (Usual Care or Placebo)
Heterogeneity: Chi2 = 10.71, df = 11 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 3.32 (P = 0.00089)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Mortality and Morbidity, Outcome 2 Total Number of CHD Events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 1 Mortality and Morbidity
Outcome: 2 Total Number of CHD Events
Study or subgroup Statin Therapy Group
Usual Care
or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ACAPS 1994 5/460 9/459 0.8 % 0.55 [ 0.19, 1.64 ]
Adult Japanese MEGA Study 66/3866 101/3966 8.9 % 0.67 [ 0.49, 0.91 ]
AFCAPS/TexCAPS 1998 163/3304 215/3301 19.3 % 0.76 [ 0.62, 0.92 ]
ASPEN 2006 72/959 75/946 6.8 % 0.95 [ 0.69, 1.29 ]
CAIUS 1996 3/151 2/154 0.2 % 1.53 [ 0.26, 9.03 ]
CARDS 2008 50/1429 74/1412 6.7 % 0.67 [ 0.47, 0.95 ]
CERDIA 2004 0/103 4/79 0.5 % 0.09 [ 0.00, 1.56 ]
HYRIM 2007 6/142 9/143 0.8 % 0.67 [ 0.25, 1.84 ]
JUPITER 2008 47/8901 95/8901 8.5 % 0.49 [ 0.35, 0.70 ]
KAPS 1995 2/214 2/212 0.2 % 0.99 [ 0.14, 6.97 ]
METEOR 2010 6/700 0/281 0.1 % 5.23 [ 0.30, 92.52 ]
PHYLLIS 2004 1/253 3/254 0.3 % 0.33 [ 0.04, 3.20 ]
PREVEND IT 2004 9/433 16/431 1.4 % 0.56 [ 0.25, 1.25 ]
WOSCOPS 390/3302 509/3293 45.7 % 0.76 [ 0.68, 0.86 ]
Total (95% CI) 24217 23832 100.0 % 0.73 [ 0.67, 0.80 ]
Total events: 820 (Statin Therapy Group), 1114 (Usual Care or Placebo)
Heterogeneity: Chi2 = 14.48, df = 13 (P = 0.34); I2 =10%
Test for overall effect: Z = 7.07 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Mortality and Morbidity, Outcome 3 Number of Fatal CHD Events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 1 Mortality and Morbidity
Outcome: 3 Number of Fatal CHD Events
Study or subgroup Statin Therapy Group
Usual Care
or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ACAPS 1994 0/460 4/459 1.5 % 0.11 [ 0.01, 2.05 ]
Adult Japanese MEGA Study 7/3866 13/3966 4.2 % 0.55 [ 0.22, 1.38 ]
AFCAPS/TexCAPS 1998 11/3304 15/3301 4.9 % 0.73 [ 0.34, 1.59 ]
ASPEN 2006 24/959 19/946 6.2 % 1.25 [ 0.69, 2.26 ]
CAIUS 1996 1/151 0/154 0.2 % 3.06 [ 0.13, 74.51 ]
CARDS 2008 18/1429 24/1412 7.9 % 0.74 [ 0.40, 1.36 ]
JUPITER 2008 9/8901 6/8901 2.0 % 1.50 [ 0.53, 4.21 ]
KAPS 1995 2/214 2/212 0.7 % 0.99 [ 0.14, 6.97 ]
PREVEND IT 2004 9/433 16/431 5.2 % 0.56 [ 0.25, 1.25 ]
WOSCOPS 170/3302 207/3293 67.4 % 0.82 [ 0.67, 1.00 ]
Total (95% CI) 23019 23075 100.0 % 0.82 [ 0.70, 0.96 ]
Total events: 251 (Statin Therapy Group), 306 (Usual Care or Placebo)
Heterogeneity: Chi2 = 7.47, df = 9 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 2.41 (P = 0.016)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Mortality and Morbidity, Outcome 4 Number of Non-fatal CHD Events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 1 Mortality and Morbidity
Outcome: 4 Number of Non-fatal CHD Events
Study or subgroup Statin Therapy Group
Usual Care
or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ACAPS 1994 5/460 5/459 0.9 % 1.00 [ 0.29, 3.42 ]
Adult Japanese MEGA Study 59/3866 88/3966 14.9 % 0.69 [ 0.50, 0.95 ]
ASPEN 2006 20/959 22/946 3.8 % 0.90 [ 0.49, 1.63 ]
CAIUS 1996 2/151 2/154 0.3 % 1.02 [ 0.15, 7.15 ]
CARDS 2008 32/1429 50/1412 8.6 % 0.63 [ 0.41, 0.98 ]
JUPITER 2008 38/8901 89/8901 15.3 % 0.43 [ 0.29, 0.62 ]
KAPS 1995 3/214 6/212 1.0 % 0.50 [ 0.13, 1.95 ]
METEOR 2010 6/700 0/281 0.1 % 5.23 [ 0.30, 92.52 ]
PHYLLIS 2004 1/253 3/254 0.5 % 0.33 [ 0.04, 3.20 ]
PREVEND IT 2004 9/433 16/431 2.7 % 0.56 [ 0.25, 1.25 ]
WOSCOPS 220/3302 302/3293 51.8 % 0.73 [ 0.61, 0.86 ]
Total (95% CI) 20668 20309 100.0 % 0.67 [ 0.59, 0.76 ]
Total events: 395 (Statin Therapy Group), 583 (Usual Care or Placebo)
Heterogeneity: Chi2 = 10.61, df = 10 (P = 0.39); I2 =6%
Test for overall effect: Z = 6.21 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Mortality and Morbidity, Outcome 5 Total Number of CVD Events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 1 Mortality and Morbidity
Outcome: 5 Total Number of CVD Events
Study or subgroup Statin Therapy Group
Usual Care
or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ACAPS 1994 0/460 6/459 0.4 % 0.08 [ 0.00, 1.36 ]
Adult Japanese MEGA Study 125/3866 172/3966 11.6 % 0.75 [ 0.59, 0.93 ]
CAIUS 1996 3/151 2/154 0.1 % 1.53 [ 0.26, 9.03 ]
CARDS 2008 80/1429 124/1412 8.5 % 0.64 [ 0.49, 0.84 ]
CERDIA 2004 2/103 12/79 0.9 % 0.13 [ 0.03, 0.55 ]
HYRIM 2007 11/142 15/143 1.0 % 0.74 [ 0.35, 1.55 ]
MRC/BHF Heart Protection 276/2006 367/1976 25.3 % 0.74 [ 0.64, 0.85 ]
PREVEND IT 2004 22/433 25/431 1.7 % 0.88 [ 0.50, 1.53 ]
WOSCOPS 584/3302 732/3293 50.2 % 0.80 [ 0.72, 0.88 ]
Total (95% CI) 11892 11913 100.0 % 0.75 [ 0.70, 0.81 ]
Total events: 1103 (Statin Therapy Group), 1455 (Usual Care or Placebo)
Heterogeneity: Chi2 = 11.63, df = 8 (P = 0.17); I2 =31%
Test for overall effect: Z = 7.66 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Mortality and Morbidity, Outcome 6 Number of Fatal CVD Events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 1 Mortality and Morbidity
Outcome: 6 Number of Fatal CVD Events
Study or subgroup Statin Therapy Group
Usual Care
or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ACAPS 1994 0/460 6/459 1.8 % 0.08 [ 0.00, 1.36 ]
Adult Japanese MEGA Study 11/3866 18/3966 5.0 % 0.63 [ 0.30, 1.33 ]
JUPITER 2008 28/8901 30/8901 8.4 % 0.93 [ 0.56, 1.56 ]
PREVEND IT 2004 4/433 4/431 1.1 % 1.00 [ 0.25, 3.95 ]
WOSCOPS 252/3302 297/3293 83.6 % 0.85 [ 0.72, 0.99 ]
Total (95% CI) 16962 17050 100.0 % 0.83 [ 0.72, 0.96 ]
Total events: 295 (Statin Therapy Group), 355 (Usual Care or Placebo)
Heterogeneity: Chi2 = 3.50, df = 4 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 2.45 (P = 0.014)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Mortality and Morbidity, Outcome 7 Number of Non-fatal CVD Events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 1 Mortality and Morbidity
Outcome: 7 Number of Non-fatal CVD Events
Study or subgroup Statin Therapy Group
Usual Care
or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Adult Japanese MEGA Study 114/3866 154/3966 87.8 % 0.76 [ 0.60, 0.96 ]
PREVEND IT 2004 18/433 21/431 12.2 % 0.85 [ 0.46, 1.58 ]
Total (95% CI) 4299 4397 100.0 % 0.77 [ 0.62, 0.96 ]
Total events: 132 (Statin Therapy Group), 175 (Usual Care or Placebo)
Heterogeneity: Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 2.30 (P = 0.022)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Mortality and Morbidity, Outcome 8 Total Number of Stroke Events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 1 Mortality and Morbidity
Outcome: 8 Total Number of Stroke Events
Study or subgroup Statin Therapy Group
Usual Care
or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ACAPS 1994 0/460 5/459 1.2 % 0.09 [ 0.01, 1.64 ]
Adult Japanese MEGA Study 50/3866 62/3966 13.8 % 0.83 [ 0.57, 1.20 ]
ASPEN 2006 27/959 29/946 6.6 % 0.92 [ 0.55, 1.54 ]
Bone 2007 1/485 0/119 0.2 % 0.74 [ 0.03, 18.07 ]
CARDS 2008 30/1429 50/1412 11.3 % 0.59 [ 0.38, 0.93 ]
JUPITER 2008 33/8901 64/8901 14.4 % 0.52 [ 0.34, 0.78 ]
KAPS 1995 2/214 5/212 1.1 % 0.40 [ 0.08, 2.02 ]
PHYLLIS 2004 1/253 0/254 0.1 % 3.01 [ 0.12, 73.58 ]
PREVEND IT 2004 7/433 4/431 0.9 % 1.74 [ 0.51, 5.91 ]
WOSCOPS 194/3302 223/3293 50.3 % 0.87 [ 0.72, 1.05 ]
Total (95% CI) 20302 19993 100.0 % 0.78 [ 0.68, 0.89 ]
Total events: 345 (Statin Therapy Group), 442 (Usual Care or Placebo)
Heterogeneity: Chi2 = 12.08, df = 9 (P = 0.21); I2 =26%
Test for overall effect: Z = 3.56 (P = 0.00037)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Mortality and Morbidity, Outcome 9 Number of Fatal Stroke Events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 1 Mortality and Morbidity
Outcome: 9 Number of Fatal Stroke Events
Study or subgroup Statin Therapy Group
Usual Care
or Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
CARDS 2008 1/1429 7/1412 21.1 % 0.14 [ 0.02, 1.15 ]
JUPITER 2008 3/8901 6/8901 31.3 % 0.50 [ 0.13, 2.00 ]
WOSCOPS 53/3302 37/3293 47.6 % 1.43 [ 0.94, 2.17 ]
Total (95% CI) 13632 13606 100.0 % 0.63 [ 0.18, 2.23 ]
Total events: 57 (Statin Therapy Group), 50 (Usual Care or Placebo)
Heterogeneity: Tau2 = 0.83; Chi2 = 6.32, df = 2 (P = 0.04); I2 =68%
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Mortality and Morbidity, Outcome 10 Number of Non-fatal Stroke Events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 1 Mortality and Morbidity
Outcome: 10 Number of Non-fatal Stroke Events
Study or subgroup Statin Therapy Group
Usual Care
or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bone 2007 1/485 0/119 0.3 % 0.74 [ 0.03, 18.07 ]
CARDS 2008 20/1429 32/1412 11.6 % 0.62 [ 0.35, 1.07 ]
JUPITER 2008 30/8901 58/8901 20.9 % 0.52 [ 0.33, 0.80 ]
PHYLLIS 2004 1/128 0/127 0.2 % 2.98 [ 0.12, 72.39 ]
WOSCOPS 141/3302 186/3293 67.1 % 0.76 [ 0.61, 0.94 ]
Total (95% CI) 14245 13852 100.0 % 0.69 [ 0.58, 0.83 ]
Total events: 193 (Statin Therapy Group), 276 (Usual Care or Placebo)
Heterogeneity: Chi2 = 3.31, df = 4 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 3.97 (P = 0.000072)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 Mortality and Morbidity, Outcome 11 Total Number of Fatal and Non-fatal
CHD, CVD and Stroke Events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 1 Mortality and Morbidity
Outcome: 11 Total Number of Fatal and Non-fatal CHD, CVD and Stroke Events
Study or subgroup Statin Therapy Group
Usual Care
or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Adult Japanese MEGA Study 134/3958 182/4051 26.6 % 0.75 [ 0.61, 0.94 ]
AFCAPS/TexCAPS 1998 116/3304 183/3301 27.1 % 0.63 [ 0.50, 0.80 ]
CARDS 2008 80/1428 124/1410 18.4 % 0.64 [ 0.49, 0.84 ]
JUPITER 2008 108/8901 189/8901 27.9 % 0.57 [ 0.45, 0.72 ]
Total (95% CI) 17591 17663 100.0 % 0.65 [ 0.58, 0.73 ]
Total events: 438 (Statin Therapy Group), 678 (Usual Care or Placebo)
Heterogeneity: Chi2 = 2.99, df = 3 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 7.20 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Mortality and Morbidity, Outcome 12 Number of Study Participants who
underwent Revascularisation.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 1 Mortality and Morbidity
Outcome: 12 Number of Study Participants who underwent Revascularisation
Study or subgroup Statin Therapy Group
Usual Care
or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Adult Japanese MEGA Study 39/3866 66/3966 14.2 % 0.61 [ 0.41, 0.90 ]
AFCAPS/TexCAPS 1998 106/3304 157/3301 34.1 % 0.67 [ 0.53, 0.86 ]
CAIUS 1996 3/151 4/154 0.9 % 0.76 [ 0.17, 3.36 ]
CARDS 2008 12/1428 18/1410 3.9 % 0.66 [ 0.32, 1.36 ]
JUPITER 2008 71/8901 131/8901 28.5 % 0.54 [ 0.41, 0.72 ]
KAPS 1995 4/214 5/212 1.1 % 0.79 [ 0.22, 2.91 ]
WOSCOPS 51/3302 80/3293 17.4 % 0.64 [ 0.45, 0.90 ]
Total (95% CI) 21166 21237 100.0 % 0.62 [ 0.54, 0.72 ]
Total events: 286 (Statin Therapy Group), 461 (Usual Care or Placebo)
Heterogeneity: Chi2 = 1.58, df = 6 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 6.38 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Lipids (mmol/L), Outcome 1 Total Cholesterol (mmol/L).
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 2 Lipids (mmol/L)
Outcome: 1 Total Cholesterol (mmol/L)
Study or subgroup Statin Therapy Group
Usual Care
or Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Adult Japanese MEGA Study 3866 -0.72 (0.8) 3966 -0.14 (0.8) 7.3 % -0.58 [ -0.62, -0.54 ]
ASPEN 2006 959 -0.51 (0.8) 946 -0.04 (0.8) 7.3 % -0.47 [ -0.54, -0.40 ]
CAIUS 1996 151 -1.01 (1.04) 154 0.18 (0.87) 7.1 % -1.19 [ -1.41, -0.97 ]
CARDS 2008 1428 -1.24 (0.84) 1410 -0.07 (0.87) 7.3 % -1.17 [ -1.23, -1.11 ]
CELL A 1996 111 -0.89 (0.86) 117 -0.18 (0.72) 7.1 % -0.71 [ -0.92, -0.50 ]
CELL B 1996 117 -0.86 (2.01) 110 0.07 (0.64) 6.5 % -0.93 [ -1.31, -0.55 ]
CERDIA 2004 103 -1 (0.86) 79 0.14 (0.85) 7.0 % -1.14 [ -1.39, -0.89 ]
Derosa 2003 24 -1.63 (0.51) 23 -0.83 (0.58) 6.8 % -0.80 [ -1.11, -0.49 ]
HYRIM 2007 42 -0.56 (0.12) 41 0 (0.11) 7.3 % -0.56 [ -0.61, -0.51 ]
JUPITER 2008 8901 -1.1 (0.8) 8901 0.8 (0.8) 7.3 % -1.90 [ -1.92, -1.88 ]
KAPS 1995 214 -1.5 (0.66) 212 0 (0.66) 7.2 % -1.50 [ -1.63, -1.37 ]
METEOR 2010 624 -2.02 (0.77) 252 0 (0.7) 7.3 % -2.02 [ -2.13, -1.91 ]
PHYLLIS 2004 253 -1.1 (0.07) 254 -0.13 (0.06) 7.3 % -0.97 [ -0.98, -0.96 ]
PREVEND IT 2004 433 -1 (1) 431 -0.2 (1.05) 7.2 % -0.80 [ -0.94, -0.66 ]
Total (95% CI) 17226 16896 100.0 % -1.05 [ -1.35, -0.76 ]
Heterogeneity: Tau2 = 0.30; Chi2 = 6891.53, df = 13 (P<0.00001); I2 =100%
Test for overall effect: Z = 7.08 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Lipids (mmol/L), Outcome 2 LDL Cholesterol (mmol/L).
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 2 Lipids (mmol/L)
Outcome: 2 LDL Cholesterol (mmol/L)
Study or subgroup Statin Therapy Group
Usual Care
or Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
ACAPS 1994 231 -1.1 (0.72) 230 -0.2 (0.69) 6.3 % -0.90 [ -1.03, -0.77 ]
Adult Japanese MEGA Study 3866 -0.74 (0.8) 3966 -0.15 (0.8) 6.6 % -0.59 [ -0.63, -0.55 ]
ASPEN 2006 959 -0.79 (0.67) 946 -0.01 (0.67) 6.5 % -0.78 [ -0.84, -0.72 ]
CAIUS 1996 151 -1.03 (0.86) 154 0.09 (0.74) 6.1 % -1.12 [ -1.30, -0.94 ]
CARDS 2008 1428 -0.93 (0.71) 1410 0.1 (0.75) 6.6 % -1.03 [ -1.08, -0.98 ]
CELL A 1996 111 -0.94 (0.89) 117 -0.21 (0.72) 5.9 % -0.73 [ -0.94, -0.52 ]
CELL B 1996 117 -0.96 (0.8) 110 -0.04 (0.64) 6.0 % -0.92 [ -1.11, -0.73 ]
CERDIA 2004 103 -0.86 (0.83) 79 0.23 (0.76) 5.8 % -1.09 [ -1.32, -0.86 ]
Derosa 2003 24 -1.61 (0.57) 23 -0.61 (0.53) 5.2 % -1.00 [ -1.31, -0.69 ]
HYRIM 2007 142 -0.39 (0.7) 143 0 (0.8) 6.1 % -0.39 [ -0.56, -0.22 ]
JUPITER 2008 8901 -1.37 (0.8) 8901 0.02 (0.8) 6.6 % -1.39 [ -1.41, -1.37 ]
KAPS 1995 214 -1.4 (0.63) 212 0.2 (0.66) 6.3 % -1.60 [ -1.72, -1.48 ]
METEOR 2010 624 -1.99 (0.67) 252 -0.05 (0.62) 6.5 % -1.94 [ -2.03, -1.85 ]
PHYLLIS 2004 253 -1.09 (0.07) 254 -0.15 (0.06) 6.6 % -0.94 [ -0.95, -0.93 ]
PREVEND IT 2004 433 -1 (0.95) 431 -0.1 (0.95) 6.3 % -0.90 [ -1.03, -0.77 ]
WOSCOPS 3302 -0.7 (0.71) 3293 0 (0.71) 6.6 % -0.70 [ -0.73, -0.67 ]
Total (95% CI) 20859 20521 100.0 % -1.00 [ -1.16, -0.85 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 2548.57, df = 15 (P<0.00001); I2 =99%
Test for overall effect: Z = 12.70 (P < 0.00001)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours treatment Favours control
65Statins for the primary prevention of cardiovascular disease (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.1. Comparison 3 Adverse Events, Outcome 1 Number of study participants who had adverse
events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 3 Adverse Events
Outcome: 1 Number of study participants who had adverse events
Study or subgroup Statin Therapy Group
Usual Care
or Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Adult Japanese MEGA Study 451/3866 397/3966 1.17 [ 1.03, 1.32 ]
AFCAPS/TexCAPS 1998 1045/3304 1126/3301 0.93 [ 0.87, 0.99 ]
ASPEN 2006 361/959 334/946 1.07 [ 0.95, 1.20 ]
Bone 2007 413/485 102/119 0.99 [ 0.92, 1.08 ]
CAIUS 1996 21/151 21/154 1.02 [ 0.58, 1.79 ]
CARDS 2008 1390/1428 1376/1410 1.00 [ 0.99, 1.01 ]
Derosa 2003 0/24 0/23 0.0 [ 0.0, 0.0 ]
JUPITER 2008 1352/8901 1377/8901 0.98 [ 0.92, 1.05 ]
KAPS 1995 107/214 95/212 1.12 [ 0.91, 1.36 ]
METEOR 2010 583/700 226/281 1.04 [ 0.97, 1.11 ]
PHYLLIS 2004 12/253 14/254 0.86 [ 0.41, 1.82 ]
PREVEND IT 2004 13/433 22/431 0.59 [ 0.30, 1.15 ]
Total (95% CI) 20718 19998 1.00 [ 0.97, 1.03 ]
Total events: 5748 (Statin Therapy Group), 5090 (Usual Care or Placebo)
Heterogeneity: Chi2 = 16.39, df = 10 (P = 0.09); I2 =39%
Test for overall effect: Z = 0.17 (P = 0.86)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Adverse Events, Outcome 2 Number of study participants who stopped
treatment due to adverse events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 3 Adverse Events
Outcome: 2 Number of study participants who stopped treatment due to adverse events
Study or subgroup Statin Therapy Group
Usual Care
or Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
ACAPS 1994 3/460 3/460 2.5 % 1.00 [ 0.20, 4.98 ]
AFCAPS/TexCAPS 1998 80/3304 68/3301 13.8 % 1.18 [ 0.85, 1.64 ]
ASPEN 2006 131/959 225/946 15.2 % 0.51 [ 0.40, 0.64 ]
CARDS 2008 122/1428 145/1410 15.0 % 0.81 [ 0.63, 1.05 ]
KAPS 1995 8/214 12/212 5.9 % 0.65 [ 0.26, 1.62 ]
METEOR 2010 79/700 22/281 11.0 % 1.50 [ 0.91, 2.45 ]
PHYLLIS 2004 23/254 33/254 9.9 % 0.67 [ 0.38, 1.17 ]
PREVEND IT 2004 23/433 33/431 10.1 % 0.68 [ 0.39, 1.17 ]
WOSCOPS 471/3302 432/3293 16.5 % 1.10 [ 0.96, 1.27 ]
Total (95% CI) 11054 10588 100.0 % 0.86 [ 0.65, 1.12 ]
Total events: 940 (Statin Therapy Group), 973 (Usual Care or Placebo)
Heterogeneity: Tau2 = 0.11; Chi2 = 40.33, df = 8 (P<0.00001); I2 =80%
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Adverse Events, Outcome 3 Number of study participants who were admitted
to hospital.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 3 Adverse Events
Outcome: 3 Number of study participants who were admitted to hospital
Study or subgroup Statin Therapy Group
Usual Care
or Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
ASPEN 2006 65/959 62/946 48.9 % 1.03 [ 0.74, 1.45 ]
JUPITER 2008 76/8901 143/8901 51.1 % 0.53 [ 0.40, 0.70 ]
Total (95% CI) 9860 9847 100.0 % 0.74 [ 0.38, 1.41 ]
Total events: 141 (Statin Therapy Group), 205 (Usual Care or Placebo)
Heterogeneity: Tau2 = 0.20; Chi2 = 9.00, df = 1 (P = 0.003); I2 =89%
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 Adverse Events, Outcome 4 Number of study participants who developed
cancer.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 3 Adverse Events
Outcome: 4 Number of study participants who developed cancer
Study or subgroup Statin Therapy Group
Usual Care
or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AFCAPS/TexCAPS 1998 252/3304 259/3301 23.6 % 0.97 [ 0.82, 1.15 ]
ASPEN 2006 29/959 15/946 1.4 % 1.91 [ 1.03, 3.53 ]
Bone 2007 53/485 8/119 1.2 % 1.63 [ 0.79, 3.33 ]
CAIUS 1996 3/151 4/154 0.4 % 0.76 [ 0.17, 3.36 ]
CARDS 2008 20/1428 30/1410 2.8 % 0.66 [ 0.38, 1.15 ]
CERDIA 2004 4/103 4/79 0.4 % 0.77 [ 0.20, 2.97 ]
JUPITER 2008 298/8901 314/8901 28.7 % 0.95 [ 0.81, 1.11 ]
KAPS 1995 0/214 2/212 0.2 % 0.20 [ 0.01, 4.10 ]
METEOR 2010 89/700 34/281 4.4 % 1.05 [ 0.73, 1.52 ]
PHYLLIS 2004 1/253 1/254 0.1 % 1.00 [ 0.06, 15.96 ]
WOSCOPS 431/3291 404/3293 36.9 % 1.07 [ 0.94, 1.21 ]
Total (95% CI) 19789 18950 100.0 % 1.01 [ 0.93, 1.10 ]
Total events: 1180 (Statin Therapy Group), 1075 (Usual Care or Placebo)
Heterogeneity: Chi2 = 11.00, df = 10 (P = 0.36); I2 =9%
Test for overall effect: Z = 0.31 (P = 0.76)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 Adverse Events, Outcome 5 Number of study participants who developed
myalgia or muscle pain.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 3 Adverse Events
Outcome: 5 Number of study participants who developed myalgia or muscle pain
Study or subgroup Statin Therapy Group
Usual Care
or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AFCAPS/TexCAPS 1998 10/3304 10/3301 0.6 % 1.00 [ 0.42, 2.40 ]
ASPEN 2006 29/959 15/946 0.9 % 1.91 [ 1.03, 3.53 ]
Bone 2007 53/485 8/119 0.7 % 1.63 [ 0.79, 3.33 ]
CARDS 2008 61/1428 72/1410 4.2 % 0.84 [ 0.60, 1.17 ]
CERDIA 2004 18/103 26/79 1.7 % 0.53 [ 0.31, 0.90 ]
JUPITER 2008 1421/8901 1375/8901 79.6 % 1.03 [ 0.97, 1.11 ]
KAPS 1995 49/214 43/212 2.5 % 1.13 [ 0.79, 1.62 ]
METEOR 2010 89/700 34/281 2.8 % 1.05 [ 0.73, 1.52 ]
WOSCOPS 117/3302 121/3293 7.0 % 0.96 [ 0.75, 1.24 ]
Total (95% CI) 19396 18542 100.0 % 1.03 [ 0.97, 1.09 ]
Total events: 1847 (Statin Therapy Group), 1704 (Usual Care or Placebo)
Heterogeneity: Chi2 = 13.53, df = 8 (P = 0.09); I2 =41%
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Not applicable
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Analysis 3.6. Comparison 3 Adverse Events, Outcome 6 Number of study participants who developed
rhabdomyolysis.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 3 Adverse Events
Outcome: 6 Number of study participants who developed rhabdomyolysis
Study or subgroup Statin Therapy Group
Usual Care
or Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Adult Japanese MEGA Study 0/3866 0/3966 0.0 [ 0.0, 0.0 ]
AFCAPS/TexCAPS 1998 1/3304 2/3301 0.50 [ 0.05, 5.51 ]
ASPEN 2006 1/1211 1/1199 0.99 [ 0.06, 15.81 ]
CARDS 2008 0/1428 0/1410 0.0 [ 0.0, 0.0 ]
JUPITER 2008 1/8901 0/8901 3.00 [ 0.12, 73.63 ]
METEOR 2010 0/700 0/281 0.0 [ 0.0, 0.0 ]
Total (95% CI) 19410 19058 1.00 [ 0.23, 4.38 ]
Total events: 3 (Statin Therapy Group), 3 (Usual Care or Placebo)
Heterogeneity: Chi2 = 0.77, df = 2 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.00 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 3.7. Comparison 3 Adverse Events, Outcome 7 Number of study participants who developed
diabetes.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 3 Adverse Events
Outcome: 7 Number of study participants who developed diabetes
Study or subgroup Statin Therapy Group
Usual Care
or Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AFCAPS/TexCAPS 1998 72/3304 74/3301 25.7 % 0.97 [ 0.70, 1.35 ]
JUPITER 2008 270/8901 216/8901 74.3 % 1.26 [ 1.05, 1.51 ]
Total (95% CI) 12205 12202 100.0 % 1.18 [ 1.01, 1.39 ]
Total events: 342 (Statin Therapy Group), 290 (Usual Care or Placebo)
Heterogeneity: Chi2 = 1.82, df = 1 (P = 0.18); I2 =45%
Test for overall effect: Z = 2.09 (P = 0.037)
Test for subgroup differences: Not applicable
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Analysis 3.8. Comparison 3 Adverse Events, Outcome 8 Number of study participants who developed
haemorrhagic stroke.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 3 Adverse Events
Outcome: 8 Number of study participants who developed haemorrhagic stroke
Study or subgroup Statin Therapy Group
Usual Care
or Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Adult Japanese MEGA Study 6/8901 9/8901 39.5 % 0.67 [ 0.24, 1.87 ]
JUPITER 2008 16/3866 14/3966 60.5 % 1.17 [ 0.57, 2.41 ]
Total (95% CI) 12767 12867 100.0 % 0.97 [ 0.54, 1.75 ]
Total events: 22 (Statin Therapy Group), 23 (Usual Care or Placebo)
Heterogeneity: Chi2 = 0.78, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
Test for subgroup differences: Not applicable
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Analysis 3.9. Comparison 3 Adverse Events, Outcome 9 Number of study participants who had elevated
liver enzymes.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 3 Adverse Events
Outcome: 9 Number of study participants who had elevated liver enzymes
Study or subgroup Statin Therapy Group
Usual Care
or Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
ACAPS 1994 3/460 3/459 3.0 % 1.00 [ 0.20, 4.92 ]
Adult Japanese MEGA Study 107/3866 104/3966 24.3 % 1.06 [ 0.81, 1.38 ]
AFCAPS/TexCAPS 1998 110/3304 70/3301 23.2 % 1.57 [ 1.17, 2.11 ]
ASPEN 2006 13/959 11/946 9.2 % 1.17 [ 0.52, 2.59 ]
Bone 2007 2/485 0/119 0.9 % 1.23 [ 0.06, 25.55 ]
CARDS 2008 12/1428 6/1410 6.8 % 1.97 [ 0.74, 5.25 ]
CERDIA 2004 1/103 0/79 0.8 % 2.31 [ 0.10, 55.90 ]
JUPITER 2008 216/8901 275/8901 27.5 % 0.79 [ 0.66, 0.94 ]
KAPS 1995 1/214 1/212 1.1 % 0.99 [ 0.06, 15.74 ]
METEOR 2010 11/700 2/281 3.3 % 2.21 [ 0.49, 9.90 ]
Total (95% CI) 20420 19674 100.0 % 1.16 [ 0.87, 1.54 ]
Total events: 476 (Statin Therapy Group), 472 (Usual Care or Placebo)
Heterogeneity: Tau2 = 0.07; Chi2 = 19.70, df = 9 (P = 0.02); I2 =54%
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Not applicable
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Analysis 3.10. Comparison 3 Adverse Events, Outcome 10 Number of study participants who developed
renal disorder.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 3 Adverse Events
Outcome: 10 Number of study participants who developed renal disorder
Study or subgroup Statin Therapy Group
Usual Care
or Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AFCAPS/TexCAPS 1998 21/3304 21/3301 4.4 % 1.00 [ 0.54, 1.83 ]
ASPEN 2006 1/1211 0/1199 0.1 % 2.97 [ 0.12, 73.05 ]
JUPITER 2008 535/8907 480/8901 94.6 % 1.12 [ 0.99, 1.27 ]
METEOR 2010 6/700 3/281 0.9 % 0.80 [ 0.20, 3.23 ]
Total (95% CI) 14122 13682 100.0 % 1.11 [ 0.99, 1.26 ]
Total events: 563 (Statin Therapy Group), 504 (Usual Care or Placebo)
Heterogeneity: Chi2 = 0.71, df = 3 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 1.72 (P = 0.085)
Test for subgroup differences: Not applicable
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Analysis 3.11. Comparison 3 Adverse Events, Outcome 11 Number of study participants who developed
arthritis.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 3 Adverse Events
Outcome: 11 Number of study participants who developed arthritis
Study or subgroup Statin Therapy Group
Usual Care
or Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
AFCAPS/TexCAPS 1998 153/3304 147/3301 65.0 % 1.04 [ 0.83, 1.31 ]
METEOR 2010 82/700 22/281 35.0 % 1.56 [ 0.95, 2.56 ]
Total (95% CI) 4004 3582 100.0 % 1.20 [ 0.82, 1.75 ]
Total events: 235 (Statin Therapy Group), 169 (Usual Care or Placebo)
Heterogeneity: Tau2 = 0.04; Chi2 = 2.13, df = 1 (P = 0.14); I2 =53%
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Treatment Compliance, Outcome 1 Treatment Compliance.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 4 Treatment Compliance
Outcome: 1 Treatment Compliance
Study or subgroup Statin Therapy Group
Usual Care
or Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Adult Japanese MEGA Study 3479/3866 2618/3966 12.9 % 1.36 [ 1.33, 1.40 ]
AFCAPS/TexCAPS 1998 2335/3304 2081/3301 12.8 % 1.12 [ 1.08, 1.16 ]
Bone 2007 422/485 103/119 11.8 % 1.01 [ 0.93, 1.09 ]
JUPITER 2008 6676/8901 6676/8901 12.9 % 1.00 [ 0.98, 1.02 ]
KAPS 1995 197/214 192/212 12.3 % 1.02 [ 0.96, 1.08 ]
METEOR 2010 697/702 273/282 12.9 % 1.03 [ 1.00, 1.05 ]
PREVEND IT 2004 321/433 286/431 11.6 % 1.12 [ 1.02, 1.22 ]
WOSCOPS 2311/3302 2305/3293 12.8 % 1.00 [ 0.97, 1.03 ]
Total (95% CI) 21207 20505 100.0 % 1.08 [ 0.98, 1.18 ]
Total events: 16438 (Statin Therapy Group), 14534 (Usual Care or Placebo)
Heterogeneity: Tau2 = 0.02; Chi2 = 479.91, df = 7 (P<0.00001); I2 =99%
Test for overall effect: Z = 1.58 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 Sensitivity Analysis, Outcome 1 Early stopping of trials and total mortality.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 5 Sensitivity Analysis
Outcome: 1 Early stopping of trials and total mortality
Study or subgroup Statin Therapy Group
Usual Care
or Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 trials stopped early
AFCAPS/TexCAPS 1998 80/3304 77/3301 1.04 [ 0.76, 1.41 ]
CARDS 2008 61/1428 82/1410 0.73 [ 0.53, 1.01 ]
JUPITER 2008 198/8901 247/8901 0.80 [ 0.67, 0.96 ]
Subtotal (95% CI) 13633 13612 0.83 [ 0.72, 0.96 ]
Total events: 339 (Statin Therapy Group), 406 (Usual Care or Placebo)
Heterogeneity: Chi2 = 2.69, df = 2 (P = 0.26); I2 =26%
Test for overall effect: Z = 2.52 (P = 0.012)
2 trials with no early stop
Adult Japanese MEGA Study 57/3958 81/4051 0.72 [ 0.51, 1.01 ]
ASPEN 2006 44/959 40/946 1.09 [ 0.71, 1.65 ]
Bone 2007 0/485 0/119 0.0 [ 0.0, 0.0 ]
CERDIA 2004 3/103 4/79 0.58 [ 0.13, 2.50 ]
KAPS 1995 4/214 5/212 0.79 [ 0.22, 2.91 ]
METEOR 2010 1/700 0/281 1.21 [ 0.05, 29.54 ]
PREVEND IT 2004 10/433 8/431 1.24 [ 0.50, 3.12 ]
WOSCOPS 106/3302 135/3293 0.78 [ 0.61, 1.01 ]
Subtotal (95% CI) 10154 9412 0.82 [ 0.69, 0.98 ]
Total events: 225 (Statin Therapy Group), 273 (Usual Care or Placebo)
Heterogeneity: Chi2 = 3.49, df = 6 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 2.23 (P = 0.026)
Total (95% CI) 23787 23024 0.83 [ 0.74, 0.92 ]
Total events: 564 (Statin Therapy Group), 679 (Usual Care or Placebo)
Heterogeneity: Chi2 = 6.20, df = 9 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 3.37 (P = 0.00076)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.90), I2 =0.0%
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Analysis 5.2. Comparison 5 Sensitivity Analysis, Outcome 2 Early stopping of trials and total CHD events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 5 Sensitivity Analysis
Outcome: 2 Early stopping of trials and total CHD events
Study or subgroup Statin Therapy Group
Usual Care
or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 trials stopped early
AFCAPS/TexCAPS 1998 163/3304 215/3301 19.2 % 0.76 [ 0.62, 0.92 ]
CARDS 2008 50/1429 74/1429 6.6 % 0.68 [ 0.48, 0.96 ]
JUPITER 2008 47/8901 95/8901 8.5 % 0.49 [ 0.35, 0.70 ]
Subtotal (95% CI) 13634 13631 34.2 % 0.68 [ 0.58, 0.79 ]
Total events: 260 (Statin Therapy Group), 384 (Usual Care or Placebo)
Heterogeneity: Chi2 = 4.35, df = 2 (P = 0.11); I2 =54%
Test for overall effect: Z = 4.97 (P < 0.00001)
2 trials with no early stop
ACAPS 1994 5/460 9/459 0.8 % 0.55 [ 0.19, 1.64 ]
Adult Japanese MEGA Study 66/3866 101/3966 8.9 % 0.67 [ 0.49, 0.91 ]
ASPEN 2006 72/959 75/946 6.7 % 0.95 [ 0.69, 1.29 ]
CAIUS 1996 3/151 2/154 0.2 % 1.53 [ 0.26, 9.03 ]
CERDIA 2004 0/103 4/79 0.5 % 0.09 [ 0.00, 1.56 ]
HYRIM 2007 6/142 9/143 0.8 % 0.67 [ 0.25, 1.84 ]
KAPS 1995 5/214 8/212 0.7 % 0.62 [ 0.21, 1.86 ]
METEOR 2010 6/700 0/281 0.1 % 5.23 [ 0.30, 92.52 ]
PHYLLIS 2004 1/253 3/254 0.3 % 0.33 [ 0.04, 3.20 ]
PREVEND IT 2004 9/433 16/431 1.4 % 0.56 [ 0.25, 1.25 ]
WOSCOPS 390/3302 509/3293 45.4 % 0.76 [ 0.68, 0.86 ]
Subtotal (95% CI) 10583 10218 65.8 % 0.76 [ 0.69, 0.84 ]
Total events: 563 (Statin Therapy Group), 736 (Usual Care or Placebo)
Heterogeneity: Chi2 = 8.65, df = 10 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 5.17 (P < 0.00001)
Total (95% CI) 24217 23849 100.0 % 0.73 [ 0.67, 0.80 ]
Total events: 823 (Statin Therapy Group), 1120 (Usual Care or Placebo)
Heterogeneity: Chi2 = 14.42, df = 13 (P = 0.35); I2 =10%
Test for overall effect: Z = 7.11 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.51, df = 1 (P = 0.22), I2 =34%
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Analysis 5.3. Comparison 5 Sensitivity Analysis, Outcome 3 Study Size for total Mortality.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 5 Sensitivity Analysis
Outcome: 3 Study Size for total Mortality
Study or subgroup Statin Therapy Group
Usual Care
or Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Over 1000 participants
Adult Japanese MEGA Study 57/3958 81/4051 0.72 [ 0.51, 1.01 ]
AFCAPS/TexCAPS 1998 80/3304 77/3301 1.04 [ 0.76, 1.41 ]
ASPEN 2006 44/959 40/946 1.09 [ 0.71, 1.65 ]
CARDS 2008 61/1428 82/1410 0.73 [ 0.53, 1.01 ]
JUPITER 2008 198/8901 247/8901 0.80 [ 0.67, 0.96 ]
WOSCOPS 106/3302 135/3293 0.78 [ 0.61, 1.01 ]
Subtotal (95% CI) 21852 21902 0.82 [ 0.74, 0.92 ]
Total events: 546 (Statin Therapy Group), 662 (Usual Care or Placebo)
Heterogeneity: Chi2 = 5.15, df = 5 (P = 0.40); I2 =3%
Test for overall effect: Z = 3.39 (P = 0.00069)
2 Under 1000 participants
Bone 2007 0/485 0/119 0.0 [ 0.0, 0.0 ]
CERDIA 2004 3/103 4/79 0.58 [ 0.13, 2.50 ]
KAPS 1995 4/214 5/212 0.79 [ 0.22, 2.91 ]
METEOR 2010 1/700 0/281 1.21 [ 0.05, 29.54 ]
PREVEND IT 2004 10/433 8/431 1.24 [ 0.50, 3.12 ]
Subtotal (95% CI) 1935 1122 0.95 [ 0.50, 1.82 ]
Total events: 18 (Statin Therapy Group), 17 (Usual Care or Placebo)
Heterogeneity: Chi2 = 0.88, df = 3 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.15 (P = 0.88)
Total (95% CI) 23787 23024 0.83 [ 0.74, 0.92 ]
Total events: 564 (Statin Therapy Group), 679 (Usual Care or Placebo)
Heterogeneity: Chi2 = 6.20, df = 9 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 3.37 (P = 0.00076)
Test for subgroup differences: Chi2 = 0.19, df = 1 (P = 0.67), I2 =0.0%
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Analysis 5.4. Comparison 5 Sensitivity Analysis, Outcome 4 Study Size for total CHD events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 5 Sensitivity Analysis
Outcome: 4 Study Size for total CHD events
Study or subgroup Statin Therapy Group
Usual Care
or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Over 1000 participants
Adult Japanese MEGA Study 66/3866 101/3966 8.9 % 0.67 [ 0.49, 0.91 ]
AFCAPS/TexCAPS 1998 163/3304 215/3301 19.1 % 0.76 [ 0.62, 0.92 ]
ASPEN 2006 72/959 75/946 6.7 % 0.95 [ 0.69, 1.29 ]
CARDS 2008 50/1429 74/1429 6.6 % 0.68 [ 0.48, 0.96 ]
JUPITER 2008 47/8901 95/8901 8.4 % 0.49 [ 0.35, 0.70 ]
WOSCOPS 390/3302 509/3293 45.3 % 0.76 [ 0.68, 0.86 ]
Subtotal (95% CI) 21761 21836 95.0 % 0.74 [ 0.67, 0.80 ]
Total events: 788 (Statin Therapy Group), 1069 (Usual Care or Placebo)
Heterogeneity: Chi2 = 8.54, df = 5 (P = 0.13); I2 =41%
Test for overall effect: Z = 6.81 (P < 0.00001)
2 Under 1000 participants
ACAPS 1994 5/460 9/459 0.8 % 0.55 [ 0.19, 1.64 ]
CAIUS 1996 3/151 2/154 0.2 % 1.53 [ 0.26, 9.03 ]
CERDIA 2004 0/103 7/79 0.8 % 0.05 [ 0.00, 0.88 ]
HYRIM 2007 6/142 9/143 0.8 % 0.67 [ 0.25, 1.84 ]
KAPS 1995 5/214 8/212 0.7 % 0.62 [ 0.21, 1.86 ]
METEOR 2010 6/700 0/281 0.1 % 5.23 [ 0.30, 92.52 ]
PHYLLIS 2004 1/253 3/254 0.3 % 0.33 [ 0.04, 3.20 ]
PREVEND IT 2004 9/433 16/431 1.4 % 0.56 [ 0.25, 1.25 ]
Subtotal (95% CI) 2456 2013 5.0 % 0.59 [ 0.39, 0.90 ]
Total events: 35 (Statin Therapy Group), 54 (Usual Care or Placebo)
Heterogeneity: Chi2 = 6.49, df = 7 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 2.44 (P = 0.015)
Total (95% CI) 24217 23849 100.0 % 0.73 [ 0.67, 0.80 ]
Total events: 823 (Statin Therapy Group), 1123 (Usual Care or Placebo)
Heterogeneity: Chi2 = 15.69, df = 13 (P = 0.27); I2 =17%
Test for overall effect: Z = 7.18 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.01, df = 1 (P = 0.31), I2 =1%
0.01 0.1 1 10 100
Favours experimental Favours control
80Statins for the primary prevention of cardiovascular disease (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A P P E N D I C E S
Appendix 1. Search Strategies 2007
CENTRAL on The Cochrane Library
#1MeSH descriptor Hydroxymethylglutaryl-CoA Reductase Inhibitors explode all trees
#2 statin or statins
#3 atorvastatin
#4 cerivastatin
#5 fluvastatin
#6 lovastatin
#7 pravastatin
#8 simvastatin
#9 lipitor
#10 baycol
#11 lescol
#12 mevacor
#13 altocor
#14 pravachol
#15 lipostat
#16 zocor
#17 rosuvastatin
#18 (hydroxymethylglutaryl next coenzyme next reductase next inhibitor)
#19 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9)
#20 (#10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18)
#21 (#19 or #20)
MEDLINE on Ovid
1 exp Hydroxymethylglutaryl-CoA Reductase Inhibitors/
2 (statin or statins).tw.
3 atorvastatin.tw.
4 cerivastatin.tw.
5 fluvastatin.tw.
6 lovastatin.tw.
7 pravastatin.tw.
8 simvastatin.tw.
9 lipitor.tw.
10 baycol.tw.
11 lescol.tw.
12 mevacor.tw.
13 altocor.tw.
14 pravachol.tw.
15 lipostat.tw.
16 zocor.tw.
17 mevinolin.tw.
18 compactin.tw.
19 fluindostatin.tw.
20 rosuvastatin.tw.
21 or/1-20
22 exp Cardiovascular Diseases/
81Statins for the primary prevention of cardiovascular disease (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
23 cardiovascular.tw.
24 heart disease$.tw.
25 coronary disease$.tw.
26 angina.tw.
27 heart failure.tw.
28 cardiac failure.tw.
29 exp Hyperlipidemia/
30 hyperlipid$.tw.
31 hypercholesterol$.tw.
32 exp Cholesterol/
33 cholesterol$.tw.
34 randomized controlled trial.pt.
35 controlled clinical trial.pt.
36 Randomized controlled trials/
37 random allocation.sh.
38 double blind method.sh.
39 single-blind method.sh.
40 or/34-39
41 exp animal/ not human/
42 40 not 41
43 clinical trial.pt.
44 exp Clinical trials/
45 (clin$ adj25 trial$).ti,ab.
46 ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).ti,ab.
47 placebos.sh.
48 placebo$.ti,ab.
49 random$.ti,ab.
50 research design.sh.
51 or/43-50
52 51 not 41
53 42 or 52
54 or/22-33
55 21 and 54 and 53
EMBASE on Ovid
1 exp Hydroxymethylglutaryl Coenzyme a Reductase Inhibitor/
2 (statin or statins).tw.
3 atorvastatin.tw.
4 cerivastatin.tw.
5 fluvastatin.tw.
6 lovastatin.tw.
7 pravastatin.tw.
8 simvastatin.tw.
9 lipitor.tw.
10 baycol.tw.
11 lescol.tw.
12 mevacor.tw.
13 altocor.tw.
14 pravachol.tw.
15 lipostat.tw.
16 zocor.tw.
17 mevinolin.tw.
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18 compactin.tw.
19 fluindostatin.tw.
20 rosuvastatin.tw.
21 or/1-20
22 exp Cardiovascular Disease/
23 cardiovascular.tw.
24 heart disease$.tw.
25 coronary disease$.tw.
26 angina.tw.
27 heart failure.tw.
28 cardiac failure.tw.
29 exp Hyperlipidemia/
30 hyperlipid$.tw.
31 hypercholesterol$.tw.
32 exp Cholesterol/
33 cholesterol$.tw.
34 exp lipid blood level/
35 or/22-34
36 21 and 35
37 random$.ti,ab.
38 factorial$.ti,ab.
39 (crossover$ or cross over$ or cross-over$).ti,ab.
40 placebo$.ti,ab.
41 (double$ adj blind$).ti,ab.
42 (singl$ adj blind$).ti,ab.
43 assign$.ti,ab.
44 allocat$.ti,ab.
45 volunteer$.ti,ab.
46 Crossover Procedure/
47 Double Blind Procedure/
48 Randomized Controlled Trial/
49 Single Blind Procedure/
50 or/37-49
51 exp animal/
52 nonhuman/
53 exp animal experiment/
54 or/51-53
55 exp human/
56 54 not 55
57 50 not 56
58 36 and 57
Appendix 2. 2 Search Strategies 2012
CENTRAL
#1MeSH descriptor Hydroxymethylglutaryl-CoA Reductase Inhibitors explode all trees
#2 hydroxymethylglutaryl*
#3 HMG-CoA*
#4 statin or statins
#5 atorvastatin
#6 cerivastatin
#7 fluvastatin
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#8 lovastatin
#9 pravastatin
#10 simvastatin
#11 lipitor
#12 baycol
#13 lescol
#14 mevacor
#15 altocor
#16 pravachol
#17 lipostat
#18 zocor
#19 mevinolin
#20 compactin
#21 fluindostatin
#22 rosuvastatin
#23 dalvastatin
#24 cranoc
#25 canef
#26 locol
#27 lochol
#28 leucol
#29 lescol
#30 monacolin
#31 medostatin
#32 mevinacor
#33 livalo
#34 pitava
#35 pitavastatin
#36 pravasin
#37 mevalotin
#38 gerosim
#39 lipex
#40 zenas
#41 crestor
#42 meglutol
#43 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14)
#44 (#15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29)
#45 (#30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42)
#46 (#43 OR #44 OR #45)
MEDLINE
1. exp Hydroxymethylglutaryl-CoA Reductase Inhibitors/
2. hydroxymethylglutaryl*.tw.
3. HMG-CoA*.tw.
4. (statin or statins).tw.
5. atorvastatin.tw.
6. cerivastatin.tw.
7. fluvastatin.tw.
8. lovastatin.tw.
9. pravastatin.tw.
10. simvastatin.tw.
11. lipitor.tw.
12. baycol.tw.
13. lescol.tw.
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14. mevacor.tw.
15. altocor.tw.
16. pravachol.tw.
17. lipostat.tw.
18. zocor.tw.
19. mevinolin.tw.
20. compactin.tw.
21. fluindostatin.tw.
22. rosuvastatin.tw.
23. dalvastatin.tw.
24. cranoc.tw.
25. canef.tw.
26. locol.tw.
27. lochol.tw.
28. leucol.tw.
29. lescol.tw.
30. monacolin.tw.
31. medostatin.tw.
32. mevinacor.tw.
33. livalo.tw.
34. pitava.tw.
35. pitavastatin.tw.
36. pravasin.tw.
37. mevalotin.tw.
38. gerosim.tw.
39. lipex.tw.
40. zenas.tw.
41. crestor.tw.
42. meglutol.tw.
43. or/1-42
44. exp Hyperlipidemias/
45. exp Cholesterol/
46. exp Cardiovascular Diseases/
47. cardio*.tw.
48. cardia*.tw.
49. heart*.tw.
50. coronary*.tw.
51. angina*.tw.
52. hyperlipid*.tw.
53. hypercholesterol*.tw.
54. cholesterol*.tw.
55. hypercholester?emia*.tw.
56. hyperlip?emia*.tw.
57. triglycerid*.tw.
58. hypertriglycerid?emia*.tw.
59. hyperlipoprotein?emia*.tw.
60. LDL.tw.
61. HDL.tw.
62. or/44-61
63. 43 and 62
64. randomized controlled trial.pt.
65. controlled clinical trial.pt.
66. randomized.ab.
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67. placebo.ab.
68. clinical trials as topic.sh.
69. randomly.ab.
70. trial.ti.
71. 64 or 65 or 66 or 67 or 68 or 69 or 70
72. exp animals/ not humans.sh.
73. 71 not 72
74. 63 and 73
75. (2007031* or 2007032* or 2007033* or 200704* or 200705* or 200706* or 200707* or 200708* or 200709* or 20011* or 2008*
or 2009* or 2010* or 2011*).ed.
76. 74 and 75
EMBASE
1. exp hydroxymethylglutaryl coenzyme A reductase inhibitor/
2. hydroxymethylglutaryl*.tw.
3. HMG-CoA*.tw.
4. (statin or statins).tw.
5. atorvastatin.tw.
6. cerivastatin.tw.
7. fluvastatin.tw.
8. lovastatin.tw.
9. pravastatin.tw.
10. simvastatin.tw.
11. lipitor.tw.
12. baycol.tw.
13. lescol.tw.
14. mevacor.tw.
15. altocor.tw.
16. pravachol.tw.
17. lipostat.tw.
18. zocor.tw.
19. mevinolin.tw.
20. compactin.tw.
21. fluindostatin.tw.
22. rosuvastatin.tw.
23. dalvastatin.tw.
24. cranoc.tw.
25. canef.tw.
26. locol.tw.
27. lochol.tw.
28. leucol.tw.
29. lescol.tw.
30. monacolin.tw.
31. medostatin.tw.
32. mevinacor.tw.
33. livalo.tw.
34. pitava.tw.
35. pitavastatin.tw.
36. pravasin.tw.
37. mevalotin.tw.
38. gerosim.tw.
39. lipex.tw.
40. zenas.tw.
41. crestor.tw.
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42. meglutol.tw.
43. or/1-42
44. exp cardiovascular disease/
45. cardio*.tw.
46. cardia*.tw.
47. heart*.tw.
48. coronary*.tw.
49. angina*.tw.
50. hyperlipidemia/
51. exp cholesterol/
52. exp lipid blood level/
53. hyperlipid*.tw.
54. hypercholesterol*.tw.
55. cholesterol*.tw.
56. hypercholester?emia*.tw.
57. hyperlip?emia*.tw.
58. triglycerid*.tw.
59. hypertriglycerid?emia*.tw.
60. hyperlipoprotein?emia*.tw.
61. LDL.tw.
62. HDL.tw.
63. or/44-62
64. 43 and 63
65. ((2007* or 2008* or 2009* or 2010* or 2010* or 2011*) not (“200701” or “200702” or “200703” or “200704” or “200705” or
“200706” or “200707” or “200708” or “200709” or “200710”)).em.
66. (random$ or placebo$ or single blind$ or double blind$ or triple blind$).ti,ab.
67. retracted article/
68. 66 or 67
69. (animal$ not human$).sh,hw.
70. (book or conference paper or editorial or letter or review).pt. not exp randomized controlled trial/
71. (random sampl$ or random digit$ or random effect$ or random survey or random regression).ti,ab. not exp randomized controlled
trial/
72. 69 or 70 or 71
73. 68 not 72
74. 64 and 65 and 73
75. limit 74 to embase
F E E D B A C K
Failure to cite CTT paper and dangerously misleading press release, 22 February 2011
Summary
Clinical Trials Services Unit and Epidemiogical Studies Unit
The Discussion of your paper erroneously stated that the CTT collaborators had not published information about the proportional
and absolute benefits of statin therapy among people with no prior history of vascular disease, although these were published in The
Lancet in November 2010 (Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive LDL-lowering
therapy: meta-analysis of individual data from 170,000 participants in 26 randomised trials of statin therapy. Lancet 2010; 376: 1670-
81). It also stated that the CTT collaborators had been “unable to provide the relevant analysis for inclusion in our review”, but we are
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not aware of having been asked by you (or anyone in your team) to provide such analyses, and wonder whether correspondence may
have gone astray.
We are concerned that these mis-statements in the Cochrane Collaboration paper (and some over-statements in the related press release,
such as the claim that “Given that low cholesterol has been shown to increase [our emphasis] the risk of death from other causes,
statins may do more harm than good in some patients”) are dangerously misleading for the public -as well as not meeting the Cochrane
Collaboration’s key principle of ‘keeping up to date’. Might it be possible for this Cochrane report to be corrected as a matter of
urgency?
Professor Colin Baigent, Professor of Epidemiology, MRC Scientist, Hon. Consultant in Public Health
Professor Rory Collins, BHF Professor of Medicine and Epidemiology
Reply
The recent CTT Lancet November 2010 paper was not available to our team at the time the review was completed and submitted
for publication to the Cochrane Database of Systematic Reviews. We agree that a data point in Figure 3 gives the proportional and
absolute effects on major vascular events of a 1mmol/l reduction in LDL cholesterol in trial participants without prior cardiovascular
disease. Our estimate of this effect and its precision is similar to the CTT estimate. I am surprised that CTT did not provide more
information on other outcomes among participants taking statins for primary prevention. In particular, others have raised the issue
of all-cause mortality in primary prevention trials (Ray et al, Arch Intern Med. 2010;170:1024-1031) and have expressed concerns
about an increased risk of diabetes in those taking statins (Sattar et al, Lancet 2010;375:735-42). We will, of course, include reference
to the CTT paper and will remove the text stating that CTT was “unable to provide the relevant analysis for inclusion in our review”.
It should be feasible to make these changes in the next issue. Work is underway to conduct a comprehensive update of this review as
soon as possible.
Following discussions with David Tovey and Rory Collins, the press release was withdrawn and a correction issued on 8 March 2011
from by David Tovey, Editor in Chief ’s office on the homepage of the Cochrane Library (http://www.thecochranelibrary.com/details/
editorial/1029211/Correction-by-David-Tovey.html). An email was sent to all recipients of that press release, and correction was
attempted of any existing versions of the press release that were still in circulation.
Shah Ebrahim, lead author of Statins for the Primary Prevention of Cardiovascular Disease and Coordinating Editor of the Cochrane
Heart Group
Contributors
Colin Baigant & Rory Collins, Shah Ebrahim
Further correspondence with CTT collaboration, 7 April 2011
Summary
22 February 2011
Taylor F et al. Statins for the primary prevention of cardiovascular disease.
Cochrane Database of Systematic Reviews 2011, Issue 1
The Discussion of your paper erroneously stated that the CTT collaborators had not published information about the proportional
and absolute benefits of statin therapy among people with no prior history of vascular disease, although these were published in The
Lancet in November 2010 (Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive LDL-lowering
therapy: meta-analysis of individual data from 170,000 participants in 26 randomised trials of statin therapy. Lancet 2010; 376: 1670-
81). It also stated that the CTT collaborators had been “unable to provide the relevant analysis for inclusion in our review”, but we are
not aware of having been asked by you (or anyone in your team) to provide such analyses, and wonder whether correspondence may
have gone astray.
We are concerned that these mis-statements in the Cochrane Collaboration paper (and some over-statements in the related press release,
such as the claim that “Given that low cholesterol has been shown to increase [our emphasis] the risk of death from other causes,
statins may do more harm than good in some patients”) are dangerously misleading for the public -as well as not meeting the Cochrane
Collaboration’s key principle of ‘keeping up to date’. Might it be possible for this Cochrane report to be corrected as a matter of urgency?
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Colin Baigent & Rory Collins
Reply 2 March 2011
Re: Statins for the primary prevention of cardiovascular disease, Cochrane Database of Systematic Reviews 2011, Issue 1.
Thanks for your letter of 22 February 2011. The recent CTT Lancet November 2010 paper was not available to our team at the time
the review was completed and submitted for publication to the Cochrane Database of Systematic Reviews. We agree that a data point
in Figure 3 gives the proportional and absolute effects on major vascular events of a 1mmol/l reduction in LDL cholesterol in trial
participants without prior cardiovascular disease. Our estimate of this effect and its precision is similar to the CTT estimate. I am
surprised that CTT did not provide more information on other outcomes among participants taking statins for primary prevention. In
particular, others have raised the issue of all-cause mortality in primary prevention trials (Ray et al, Arch Intern Med. 2010;170:1024-
1031) and have expressed concerns about an increased risk of diabetes in those taking statins (Sattar et al, Lancet 2010;375:735-42).
We will, of course, include reference to the CTT paper and will remove the text stating that CTT was “unable to provide the relevant
analysis for inclusion in our review”. It should be feasible to make these changes in the next issue.
The press release was referring to the association of low blood cholesterol (not cholesterol lowering by statins) with haemorrhagic
stroke which has been shown by several observational cohorts, including a large Korean civil servants cohort (n=3900 haemorrhagic
strokes), but these associations may be confounded. It would obviously be of great value to have a more reliable estimate of this effect by
randomization to statins than that reported in the recent CTT paper (RR 1.12 (95% CI: 0.93, 1.35) per 1 mmol/L reduction in LDL
cholesterol, webfigure 8) which might be achieved if more trials provided this outcome. More robust estimates would be particularly
helpful for low and middle income countries where underlying rates of haemorrhagic stroke remain high and statins, as part of a
“polypill” strategy, are being promoted for primary prevention.
We are already working on a full update of the review and have 7,000 citations to work through inclusion/exclusion criteria. In addition
to the changes for the next issue, if you want I can arrange to have your letter and my response entered in the correspondence section
linked to the review. This would enable your concerns to be immediately linked to the review and be readily available to readers of the
review. Let me know your preference.
Shah Ebrahim
4 March 2011
Dear Shah
Thank you for your response. One quick point of clarification, the press release actually says “low cholesterol has been shown to
increase [my emphasis] the risk of death from other causes” which is clearly quite different from what you have written in the second
paragraph of your letter and is dangerously irresponsible. I wondered, therefore, if - before considering publication - you would like to
make this error clear in your letter and ensure that the statement in the press release is formally retracted.
Rory Collins
04 March 2011
Dear Rory
I agree the wording is quite wrong. The press statement has not been published, nor is it available to readers of the review itself. I will
add a sentence saying that a press release about the review contained a seriously misleading statement that “low cholesterol has been
shown to increase the risk of death from other causes”.
Shah Ebrahim
4 March 2011
Thank you for your proposal to modify your letter which is fine as far as it goes. The statement in this press release (which engendered
wide publicity) is, however, so dangerously wrong that I think the Cochrane Collaboration is obliged to issue a public retraction.
Please could you forward my correspondence to whoever is responsible for dealing with such serious misrepresentations within the
Collaboration?
Rory Collins
4 March 2011
In the first instance, if we have published something that is misleading or incorrect in the press release I would suggest that we issue a
correction in the release accompanying the next issue. I would like to explore with the writer of the release how this happened, as this
is the first time that we have had such a complaint in relation to a press release, to the best of my knowledge. Having said that I am
responsible for the sign off of press releases so that any error is entirely my responsibility.
I am making some enquiries as a matter of urgency and will let you all know when we have a proposed course of action.
David Tovey
4 March 2011
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Shah Ebrahim has confirmed that the statement is wrong (see below) and, in public health terms, it is potentially a far more serious
misrepresentation than that of the risks of MMR by Wakefield and The Lancet. As a consequence, I think it requires an urgent and
specific response by the Cochrane Collaboration and should not just be “buried” in a routine press release.
Rory Collins
8 March 2011
This is to update you in relation to our current plans in relation to correction of the press release.
Firstly, we are will contact via email in the next 48 hours, all individuals and agencies that received the original press release for Issue
1 and explain the need for a correction of the offending sentence. Secondly, we will publish a correction on The Cochrane Library
homepage explaining the error. I anticipate that this will happen later today. Thirdly we will do our utmost to ensure that anywhere
where the press release is still “live”, it is modified to a more satisfactory form of words.
The Cochrane Collaboration sets a high value on quality, scientific rigour and transparency. In this instance we are grateful to you for
pointing out an error in the press release that had evaded our editorial system. Please be assured that we regarded this as a serious matter,
and have sought to implement visible and appropriate measures to correct the error. We have also learned lessons from the episode that
once implemented will reduce the chance of a similar event in the future.
David Tovey
10 March 2011
Thank you for taking some steps towards dealing with this problem as the errors of fact in both the press release, as well as those in
the related paper (see our original letter to Shah Ebrahim and his reply: attached), have had a damaging effect on public health (as
well as on the credibility of the Cochrane Collaboration). It is very much to your credit that you wish to take final responsibility (as
editor) for these errors, but should not the authors also take some of the responsibility (rather than just passing the buck) since they
presumably approved the press release which quotes them?
I have now had an opportunity to read your Correction on the Cochrane Library website and, though welcome, it seems to me that it
is incomplete (given the errors in the original paper) and, indeed, is misleadingly half-hearted. For example, Shah Ebrahim accepts in
his letter to us that, by contrast with what he had claimed in his paper, results for the highly statistical benefits in patients with no prior
cardiovascular disease (risk ratio for major vascular events: 0.75; 95% CI 0.69 - 0.82) had been published nearly 3 months beforehand.
Your Correction would have been an opportunity to put that straight, rather than to assert that such errors do “not impact in any way
on the validity of the accompanying Cochrane Review”. Similarly, please could you explain why the claim in the press release that “low
cholesterol has been shown to increase the risk of death from other causes, statins may do more harm than good” is, according to the
assertion in your correction, “irrelevant to the underlying question being evaluated”? This does not seem to be correct.
I’m sorry not to have replied to your letter sooner, but I was waiting to see the Correction before doing so and was looking for it
on the Cochrane Collaboration website, where it does not appear. As well as having it on the Cochrane Library website, would it
not be appropriate to put this Correction (or, preferably, a more accurate one) on the Cochrane Collaboration website (and any other
Cochrane websites), especially since the statin paper is one of its featured reviews?
I do hope that you will reconsider the partial (in more than one sense) attempt that you’ve made so far to redress the serious harm that
has been caused to public health by the Cochrane Collaboration and its misinterpretation of the available evidence (which does not
seem to be at all consistent with your key principles).
Rory Collins
10 March 2011
I suspect we have reached an impasse. I really don’t accept that the response was half-hearted. To repeat, we have placed a highly visible
correction on the homepage of the product that was the subject of the press release, we have sent an email to all recipients of that press
release, and we have sought to correct any existing versions of the press release that are still in circulation.
I, not the Co-ordinating Editor, sign off the press release, so this was my error alone. It was, as you pointed out, a seriously incorrect
message - implying that the very act of reducing your serum cholesterol might cause early death - and could, if acted upon have caused
public harm. For that reason I recognised the need to act decisively and swiftly to correct any wrong impression. I made the point in
the correction that the press release mistake was based on a misunderstanding of the Cochrane Review, which had explicitly explained
that any possible association was highly unlikely to be based on cause and effect. Therefore I believe it was correct to be clear that the
press release was distinct from the review.
I recognise that you have also raised questions in relation to the content of the review. As Shah describes in his response, he has taken on
board your comments, explained why the Lancet paper was not considered in the original published version, and has sought to amend
the review appropriately at the earliest opportunity. For technical /publication reasons there will be an inevitable but short delay before
the changes are published.
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I am aware that you are unlikely to agree, but I am confident that our response to the questions you have raised in relation to the press
release and the review has been appropriate, open and positive.
David Tovey
11 March 2011
I’m extremely grateful both for your careful response to my email and for what you’ve been able to do to rectify this problem. I did
have a couple of questions in my previous email which I’d be grateful if you’d consider. First, might it be possible to put the Correction
on the Cochrane Collaboration website as well, since that would be an obvious place where people alerted by the original press release
would go? Second, why do you say in the Correction that the claim in the press release that “low cholesterol has been shown to increase
the risk of death from other causes, statins may do more harm than good” is “irrelevant to the underlying question being evaluated” by
this meta-analysis of whether statins do more harm than good? I had thought that this Correction would have provided an opportunity
to indicate that errors in the original paper would also be corrected at the earliest possible opportunity.
Again, thanks for taking the issue so seriously and for going as far as you have towards repairing the damage caused.
Rory Collins
Reply
See above
Contributors
Colin Baigent & Rory Collins, Shah Ebrahim
22nd Febuary 2012
Summary
Feedback: Dear respected authors and editors of the Cochrane Heart Group, First, in the abstract of the systematic review, statistically
significant relative risk reductions were reported for all-cause mortality, non-fatal CVD events, and revascularisations. However, I had
trouble applying this knowledge in practice because there was no mention of the absolute risk reduction or number needed to treat
associated with statin use in this clinical setting. I thought these two values would be of clinical relevance since the review defined
primary prevention as treating people without evidence of existing cardiovascular disease, who would be expected to have low baseline
risks. Furthermore, despite the statistically significant relative risk reductions of key outcomes without an increase in adverse events
found by this review, the authors advised caution before prescribing statins for primary prevention. This was a point of confusion for
me, as I could not understand how the authors came to that conclusion. I think that because many people in the world have only access
to the Cochrane abstracts and plain language summary, the rationale for the conclusions should be explicit to the reader. Lastly, on the
abstract page this review was assessed as up-to-date on September 7, 2007, even though it was published on January 19, 2011. I was
not sure if that was a mistake.
With Kind Regards,
Qiming Roger Wu
BSc, BSc(Pharm), RPh, MD Candidate
Submitter agrees with default conflict of interest statement: I certify that I have no affiliations with or involvement in any organization
or entity with a financial interest in the subject matter of my feedback.
Reply
Dear Qiming Roger Wu,
Thank you for your feedback on this review of statins for primary prevention of cardiovascular disease. You would like to see absolute
risk differences and numbers needed to treat. We have not provided these as they are often misleading in primary prevention. The
absolute levels of CVD risk used will depend on a) what is included in ’CVD’ (e.g. new angina cases, revasularisations), b) the population
in which you practice (CVD incidence varies markedly between countries), c) age group and sex of the population considered. The
91Statins for the primary prevention of cardiovascular disease (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
relative risk reduction figure is stable across outcomes, populations, age and sex groups. The NNT is not and presenting several NNTs
is confusing for the reader.
You are concerned about why we recommend caution in using statins for primary prevention despite the statistically significant relative
risk reduction. This is because the quality of the trials is variable (early stopping, selective reporting of outcomes), many do not report
any adverse events (which is unlikely to be true), and guidelines in UK, USA and Europe do not recommend their use at levels below
20% 10-year risk of CVD. This is discussed in detail in the main text but not in the abstract for reasons of space. In the abstract we say:
’Other potential adverse events were not reported and some trials included people with cardiovascular disease. Only limited evidence
showed that primary prevention with statins may be cost-effective and improve patient quality of life.’ This gives some, but not all,
of the rationale for use with caution. You question whether the review is as out of date as it appears. I am afraid it is. This is because
doing a Cochrane review on statins requires searching for relevant papers - in this case we had to sift through thousands of abstracts of
papers, retrieve hundreds of full papers, assess them in duplicate to reach our final 14 trials for consideration. This takes time and in
this case was made worse as the key authors were relocated to work in India on another project that took priority over this review. We
have conducted an update and hope that this will be published before the end of 2012.
Thank you for your interest in our work.
Best wishes, Shah Ebrahim
Contributors
Qiming Yu, Shah Ebrahim
Response to Taylor et al (2013) Statins for primary preventionof cardiovascular disease
Summary
Dear Colleagues,
I am writing to express concerns about the Cochrane Review update of statins for primary prevention (Taylor et al 2013.) I have three
principle concerns which involve Taylor et al’s treatment of 1) potential commercial bias, 2) data transparency, and 3)patient safety.
Recent research indicates that commercial bias may be an important factor in evaluating the validity of published trial data and may be
more important than a checklist of technical factors in determining bias. Bero, Lexchin, Lundh and other colleagues, for example, have
pointed out a variety of issues in this regard (eg Bero et al 2007; Roseman et al 2012; Lundh et al 2012). Most recently, describing the
research of Lundh et al’s ( 2012) Cochrane Review on industry sponsorship and research outcomes, Bero (2013; JAMA Intern Med)
has stated that standard assessment tools do not adequately grapple with risk of bias. She noted that Lundh et al (2012) reviewed nine
studies with seemingly low risk of bias but the relationship between sponsorship and outcomes was in fact stronger. The Cochrane
authors, citing Als-Nielsen (2003) note the possibility of commercial bias briefly but fail to explain why they do not consider it more
fully in their analysis.
Will the authors clarify why they did not fully address commercial sponsorship as a risk of bias?
Taylor et al (2013) rely heavily on industry-sponsored trials and the meta-analysis by the CTT indicating that the CTT’s commercial
sponsorship isanalysis rests in their use of patient-level data. However, it is known that many scholars have asked the CTT for data
without success (interalia Criqui and Golomb 2004, Walsh and Pignone 2004, Petretta 2008.) As I understand the Review by Taylor
and colleagues they seem not to have reviewed that data but are relying on the CTT’s interpretations. Currently many scholars are asking
for transparency and the release of primary source data like Clinical Study Reports and patient-level data (eg Doshi and Jefferson) so
that the larger scientific community can be more fully informed. This broader perspective is important in understanding both benefit
and harm through a lens other than that provided by industry.
Will the authors clarify why they did not ask for full transparency but seemingly relied on CTT analysis?
In terms of issues related to harm, the Review is both troubling and confusing. It is known that harms are under-reported in commercial
trials. The Cochrane authors state that 12 trials provided data on Adverse Events, indicating that one third did not provide data on
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AEs. They previously stated (page 3) that the trial authors were contacted to obtain further details. It is, thus, not clear if the AE data
was withheld from the Cochrane reviewers or were not collected in the original trials. The authors state (page 14) that reporting of
adverse events in the statin trials is relatively poor, since there is a failure to provide important details of type and severity of AEs. But
they then state with (no citations) that it “seems unlikely that major
life-threatening hazards associated with statin use exist.” And they go on to state that potential non-fatal but serious adverse events have
not been assessed in statin trials. They briefly touch on the recent work by Hippsley-Cox (20120) but seem to discount the value of
database analysis for detecting statin harm. It is, thus, not clear why Taylor and colleagues have chosen to deem statins safe for primary
prevention for men and women on the basis of clinical trial data with serious limitations in safety information. Nor is it clear why they
did not consider information about harm from a wider variety of sources including advisories from countries like New Zealand, UK
and the USA. Many sources indicate that clinical trials are not geared towards
real-world experiences of harm. For example, Fernandez and colleagues at the Cleveland Clinic (2011) state that statin myopathy is a
common experience that is not reflected in clinical trials and that muscle symptoms occurred in up to 20% of patients on statins. They
point out that real-world conditions should be considered, and note the relatively low level of myalgia (1%-5%) described in clinical
trials. Other institutions have, like the Mayo Clinic, have created Statin Intolerance
Clinics acknowledging people’s every day experiences with statin harms. Oskarsson (2011; Neurology) states that there is particular
concern about necrotizing statin myopathy wherein recovery does not occur with cessation of statin-exposure. (See also research by
rheumatologists like Mammen and colleagues on treatments for statin-associated autoimmune necrotizing myopathies.)
Pharmacovigilance can play an important role in detecting signals of harm, which the Cochrane authors do not fully consider. Sakaeda
et al (2011) analyzed data on muscular and renal events in FDA data base and found evidence of signals of harm warranting clinical
trial research. There is also an important social context in adverse event reporting. Research indicates adverse event reporting to be low,
possibly because of failure to recognize statin associated symptoms (Dirks and Jones,
2006) or physician reluctance to report (Golomb et al., 2007.) Taylor and colleagues have also not dealt with the issue that statins are
considered a category X drug in the USA and are associated with miscarriage and birth defects (see for example Edison and Muenke,
2004 and Prescrire 2005.) Taylor and coseem to suggest that women of child-bearing capacity (over age 35; page 15) would benefit
from statins without considering this important harm. Taylor and colleagues indicate that in using CTT patient level data they have
examined the “totality of evidence” for primary prevention
statin use.
This does not seem possible. I am concerned that the voices of patients are not heard in this review. I do not see evidence of pro-active
research strategies addressing patient safety. The importance of interrogating the quality of safety reporting in clinical trials is seen as
valuable within the research community but it is raised in a confusing way in this review; both acknowledging problems and then
discounting their relevance. Other sources of data are not adequately considered.
Will the authors explain what they mean by “the totality of evidence” and why they have not attempted to proactively secure safety
data from trialists nor consider other forms of independent information about statin-related harms?
Harriet Rosenberg, York University, Health and Society Program (retired)
Reply
Thank you for your interest in our review. We respond to your questions and hope you find them helpful in understanding our
approach, both its strengths and its limitations.
1. Will the authors clarify why they did not fully address commercial sponsorship as a risk of bias?
The potential bias associated with commercial sponsorship of trials is well-recognised. We collected and reported information on the
funding source of all trials included in our review. We were unable to evaluate this form of potential bias through comparison of effect
sizes between commercially funded trials and non-commercially funded trials, since every trial was commercially funded. We have
addressed commercial sponsorship to the extent possible in this circumstance. We would be pleased to learn of alternative approaches
in these circumstances.
2. Will the authors clarify why they did not ask for full transparency but seemingly relied on Cholesterol Treatment Trialists (CTT)
analysis?
Our analysis did not rely on the CTT analyses. Our meta-analyses are based on published data from trials on statins. CTT is based
on individual patient data and covers an overlapping set of statin trials in both primary and secondary prevention. We are aware that
attempts to obtain individual patient data from CTT does not appear to be feasible, and we did not ask the CTT investigators for data
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as we did not require their data to carry out our systematic review. It is important to recognise that in any systematic review using
Cochrane methods a thorough search is made for all relevant trials, independent of source of funding. We then conducted our analysis
using published data and made requests to the individual trial authors, where necessary, for data on specific outcomes. As the CTT had
published highly relevant analyses since our 2011 publication, it was imperative for us to update our review in light of their findings.
Our findings obtained from the published literature and findings from the CTT are remarkably similar, so we do not believe that there
are any issues with the integrity of their analyses.
3. Will the authors explain what they mean by “the totality of evidence” and why they have not attempted to proactively secure safety
data from trialists nor consider other forms of independent information about statin-related harms?
We considered the randomized evidence in this Cochrane review and on that basis believe we have the totality of this evidence. We
have attempted to get additional information from trialists but did not set out to duplicate successful efforts that have others have made
to get additional data. CTT have been particularly successful in this regard (as have others with respect to type 2 diabetes). Individual
patient level data are needed to do this well and is a long term goal for our group. We have also considered other non-randomized
data in our discussion.
We concluded that it “seems unlikely that major life-threatening hazards associated with statin use exist.” This is based on the all-
cause mortality relative risk of 0.86 (95% CI 0.79 to 0.94). This means that, overall, any unintended effect of statins that was severe
enough to cause death would be highly unlikely as we do not see any increased overall death rate on statins. We accept that trials
generally do not report unintended effects of treatments well, and statin trials are no exception.
The analyses from the CTT have explored the possibility of hazards due to cancers and found no evidence of any increased risk of any
cancer. We believe these data are reliable and are consistent with our own analyses from the trial reports. We also considered myalgia/
rhabdomyolosis, type 2 diabetes, haemorrhagic stroke, liver dysfunction, renal dysfunction and arthritis.
We also examined adherence with treatment rates and found 77% participants and 70% in the placebo group complied with treatment;
RR 1.08 (0.98 to 1.18), indicating that while 23-30% of patients stopped treatment, this was more common in those taking placebo
than in those taking statins.
We have not made any specific reference to use of statins in women of child-bearing age, in whom it would be most unlikely for statins
to be indicated. We do report that women gain similar benefit to men, which was not clear in previous reviews.
With regard to other potentially serious, but non-fatal unintended effects of statins, we do not discount Hippsley-Cox’s report (or
Smeeth’s report) as large scale observational data are often the only way of determining possible unexpected harms. However, they are
prone to confounding and do not provide the robust evidence that randomized trials do.
There are many observational reports of harms associated with statins, and this literature frequently reports contradictory findings.
We are currently conducting a separate systematic review of these studies and are also conducting a further large scale primary care
database analysis. These studies are complex to perform, have taken separate funding to conduct, yet should be ready for submission
for publication later this year.
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